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I ABBREVIATIONS 
Steroids 
Table 1: Names, abbreviations and numbers of steroids mentioned in this work 
Trivial name Chemical name Abbreviation Number 
Cholesterol Cholest-5-en-3β-ol - 1 
Pregnenolone 3β-Hydroxypregn-5-en-20-one - 2 
Progesterone Pregn-4-ene-3,20-dione - 3 
17α-OH-pregnenolone 3β,17α-Dihydroxypregn-5-en-20-one - 4 
17α-OH-progesterone 17α-Hydroxy-pregn-4-ene-3,20-dione - 5 
Dehydroepiandrosterone 3β-Hydroxyandrost-5-en-17-one DHEA 6 
Androstenedione Androst-4-ene-3,17-dione AED 7 
Androstenediol Androst-5-ene-3β,17β-diol - 8 
Testosterone 17β-Hydroxyandrost-4-en-3-one T 9 
5α-Dihydrotestosterone 17β-Hydroxy-5α-androstan-3-one 5αDHT 10 
Estrone 3-Hydroxyestra-1,3,5(10)-trien-17-one E1 11 
Estradiol Estra-1,3,5(10)-triene-3,17β-diol E2 12 
Estriol Estra-1,3,5(10)-triene-3,16α,17β-triol E3 13 
5α-Androstanediol 5α-Androstane-3α,17β-diol 5αAdiol 14 
Androsterone 3α-Hydroxy-5α-androstan-17-one A 15 
5α-Androstanedione 5α-Androstane-3,17-dione 5αAD 16 
5β-Dihydrotestosterone 17β-Hydroxy-5β-androstan-3-one 5βDHT 17 
5β-Androstanediol 5β-Androstane-3α,17β-diol 5βAdiol 18 
Etiocholanolone 3α-Hydroxy-5β-androstan-17-one Etio 19 
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Other abbreviations 
3D 3-Dimensional 
3R Reduce, Replace, Refine 
AAF Adverse analytical finding 
AAS Anabolic androgenic steroids 
ABP Athlete Biological Passport 
ACE Angiotensin-converting enzyme 
ADAMS Anti-Doping Administration and Management System 
AKR Aldo-keto reductase 
APF Adverse Passport Finding 
Arg Arginine 
ASS Acetylsalicylic acid 
AT1 Angiotensin II receptor subtype 1 
C18, C19 or C21 Structure with 18, 19 or 21 carbon atoms 
C-3, C-17 or C-21 Carbon number 3, 17 or 21 in steroid (Figure 1) 
CCB Calcium channel blocker 
COX Cyclooxygenase 
CYP Cytochrome P450-enzyme 
EAAS Endogenous anabolic androgenic steroids 
ED Endocrine disruptor 
EU European Union 
EURL ECVAM European Union Reference Laboratory for alternatives to animal testing 
GC Gas chromatography 
GC-C-IRMS Gas chromatography-combustion-isotope ratio mass spectrometry 
GC-MS Gas chromatography-mass spectrometry 
GC-MS/MS Gas chromatography-tandem mass spectrometry 
GC-QQQ Gas chromatography-triple quadrupole mass spectrometry 
GC-q-ToF Gas chromatography-time-of-flight-mass spectrometry 
hCG Human chorionic gonadotropin 
HLM Human liver microsomes 
HRMS High-resolution mass spectrometry 
HSD Hydroxysteroid-dehydrogenase 
ISL International Standard for Laboratories 
Iso rh enzyme Isolated recombinant human enzyme 
ISTI International Standard for Testing and Investigations 
JRC Joint Research Centre 
LC Liquid chromatography 
VIII  Abbreviations 
LC-MS Liquid chromatography-mass spectrometry 
LC-MS/MS Liquid chromatography-tandem mass spectrometry 
MSTFA N-methyl-N-(trimethylsilyl)-trifluoroacetamide 
NH4I Ammonium iodide 
NSAID Non-steroidal anti-inflammatory drug 
OECD Organization for Economic Co-operation and Development 
OTC Over the couter 
PPI Proton pump inhibitor 
QQQ Triple quadrupole mass spectrometry 
S.pombe Schizosaccharomyces pombe 
S9 9000 g Supernatant; detailed explanation on page 18 (Chapter 2.2.2.) 
SDR Short-chain dehydrogenase/reductase 
SSP Suspicious steroid profile 
TA Testing authority 
TD Technical document 
UDP Uridine diphosphate 
WADA World Anti-Doping Agency 
Whole-cell BT Whole-cell biotransformation 
WMA World Medical Association 
Δ1 or Δ4 Double bond in position 1 or 4 of steroid 
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1 INTRODUCTION AND AIM OF THE PROJECT 
e knowledge of metabolism in general and steroid metabolism in particular is of high 
importance for many research fields. Expertise in this field represents a valuable tool to, among 
others, develop effective detection methods or straightforwardly interpret analytical results. All 
areas where steroid detection is of importance hence depend on research providing insights in 
metabolic processes and their influence on steroid balance in humans. In particular, this work aims 
to illustrate the significance of metabolic studies in the field of anti-doping analysis exemplarily on 
the metabolism and investigations on metabolic routes of anabolic androgenic steroids (AAS). is 
example was chosen, as it comprises several challenges in steroid detection which are in 
accordance with multiple other disciplines. Subsequently the broader relevance will be discussed. 
Detection of steroids in anti-doping analysis is of high importance, to defend the spirit of sport. 
Besides multiple beneficial physical and psychological aspects of sport, the principle of “higher, 
faster, further” is and probably has always been a key element especially for meritocratic athletes. 
Factors like training, nutrition, regeneration, mental strength and equipment are of importance to 
guarantee the best performance an athlete is able to achieve. Still, the spirit of sport must never be 
forgoen alongside the endeavour to perform beer than others. Even though, the majority of 
athletes respects the rules of fair play, there are, and again have always been, athletes not following 
these rules by using certain methods or substances to enhance their performance and to derive an 
unfair benefit from that. To prevent this acting, in the mid-1960s first substances were banned to 
be used as doping in sports. In 1999 the World Anti-Doping Agency (WADA) was founded “[…] to 
promote, coordinate and monitor the fight against doping in sport in all its forms” [1]. 
In this context AAS, used by athletes as performance enhancing drugs, are by far the most 
detected substances in anti-doping tests [2]. To detect the use of AAS, concentrations of selected 
steroids, their metabolites and precursors are measured in urine samples collected from the athletes 
in and out of competition. Testing procedures have considerably improved during the last years 
and nowadays are and have to be able to detect trace-amounts of analytes (in the lower ng/mL 
range) in the collected samples [3]. Nonetheless, a continuous improvement of the applied methods 
is of paramount importance as not only the methods of the laboratories, but also the methods of 
the dopers are improving. e use of novel designer steroids, meaning steroids which are designed 
to complicate detection, pseudo endogenous steroids, meaning endogenous steroids administered 
exogenously, or very minor doses of substances are only some of the challenges anti-doping 
laboratories have to master. 
e results presented in this thesis are aiming to contribute to overcome these challenges and 
provide valuable insights not only for anti-doping research but also for other fields where steroid 
detection and analysis is of importance. 
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2 THEORETICAL BACKGROUND 
2.1 Human steroid hormones and their metabolism 
e human endocrine system consists of glands excreting chemical messengers (hormones) 
which regulate distinct functions in the body. Even if characterized through different chemical 
structures these hormones all act at very low concentrations. e class of human steroid hormones 
consist of a lipophilic steran body with different modifications. Based on their structure and 
function, they can be divided into five major categories: two corticosteroidal groups: mineralo- and 
glucocorticoids and three groups of sexual hormones: progestagens, estrogens and androgens. 
ey all originate from cholesterol with a cholestane backbone and have different backbone 
structures themselves, as displayed in Figure 1. 
 
Figure 1: Steroid backbone of human steroid hormones and their precursor cholestane (a): pregnane (b), estrane 
(c) and androstane (d) with exemplary numbering of carbon atoms (C1-C19) and rings (A-D) 
Endogenous corticosteroids (mineralo- and glucocorticoids) and progestagens have a pregnane 
backbone with a C21 structure. Endogenous androgens consist of an androstane backbone with a 
C19 structure and estrogens have a C18 structure consisting of an estrane base. All of them have 
cholesterol (structure (1) in Figure 2) with a cholestane body as metabolic precursor. e different 
groups of steroid hormones distinguish themselves not only in their structure and induced effects 
in the human body but also in their main location of biosynthesis. Besides their principal location 
of biosynthesis, steroids may be synthesized in minor quantities in other body tissues (e.g. 
estradiol-formation in postmenopausal women). Mineralo- and glucocorticoids and minor amounts 
of androgens are produced in the adrenal cortex. Estrogens, progestagens and androgens are 
mainly produced in the male and female sexual organs. e naturally occurring progestagen 
progesterone is mainly produced in the corpus luteum and in the placenta of pregnant women. e 
androgen testosterone is primarily produced in the testis of males and for females in smaller 
amounts in the ovary and in the adrenal gland [1, 2]. Estrogens in females are mainly synthesized 
in the ovaries but also in minor amounts in the breast, brain, bone and adipose tissue. In men 
estrogens are generated from testosterone via aromatization in the testis [4]. e (simplified) 
eoretical Background  11 
biosynthesis pathway of human steroid hormones from cholesterol without tissue specificity is 
depicted in Figure 2. 
e production of sex hormones is regulated by superordinated hypothalamus hormones via 
feedback mechanisms [5]. Aer secretion of sex hormones into the circulation, they bind to 
transport- or plasma-proteins which function as carrier in the body. ese carriers are needed due 
to the high lipophilicity of steroids. In their target cell, steroid hormones bind to cytosolic steroid 
receptors, enter the nucleus as steroid-receptor-complex and induce the production of target genes 
(transcription factors). Due to their lipophilic structure human steroid hormones, as well as 
synthetic steroids, undergo both, phase I and phase II metabolism before their renal excretion. 
 
Figure 2: Simplified biosynthesis of human steroid hormones deriving from cholesterol (1). Green numbers 
indicating progestagens (C21): pregnenolone (2), progesterone (3), 17α-OH-pregnenolone (4) and 17α-OH-
progesterone (5); Blue numbers indicating androgens (C19): dehydroepiandrosterone (6), androstenedione (7), 
androstenediol (8), testosterone (9) and 5α-dihydrotestosterone (10); red numbers indicating estrogens (C18): 
estrone (11), estradiol (12) and estriol (13). Corresponding enzymes in squared brackets 
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2.1.1 Metabolism of androgens 
is work investigates predominantly phase I metabolism (reduction, oxidation, hydroxylation 
and epimerization) of androgens. To briefly mention phase II metabolism, most relevant reactions 
for androgens are glucuronidation via UDP-glucuronosyltransferases and sulphation via 
sulfotransferases. Since the complete endogenous steroid metabolism is very complex and involves 
several tissues, tissue-passages, conjugation and deconjugation steps [6], this chapter wants to give 
some basic background information on relevant phase I metabolites and their generation in 
humans. e focus is laid on important structures for this work.  
Enzymes involved in phase I metabolism of androgens are cytochrome P450-enzymes (CYPs) 
and hydroxysteroid-dehydrogenases (HSDs), which can be subdivided into the enzyme super 
families of short-chain dehydrogenases/reductases (SDRs) and aldo-keto reductases (AKRs) [7]. 
CYPs mainly catalyse hydroxylations on the steroid backbone which are mostly irreversible. In 
androgens, they are of relevance in so called minor metabolic pathways, as the excretion of these 
metabolites into urine (as phase II conjugates) is extremely low [1]. Hence, they do not play an 
important role in the detection of pseudo endogenous anabolic steroid administration in doping 
control analysis (later discussed in Chapter 2.3) [3]. CYP enzymes and their minor metabolic 
pathways are nonetheless important to investigate, as formed metabolites may improve the 
detectability of synthetic AAS and so-called designer-steroids, meaning steroids designed to 
complicate detection. is is mostly achieved by structure modifications of already known 
compounds [8, 9]. Especially in the discovery of new and/or longer detectable metabolites for 
synthetic AAS, reactions catalysed by CYPs are of relevance [10, 11]. 
Important HSDs in steroid metabolism are, beside others, 3αHSDs (AKR1C1-AKR1C4), 5α- and 
5β-reductase (SDR5A and AKR1D1) and 17βHSDs (AKR1C3) [6]. Selected noteworthy 
metabolizations catalysed by CYP-enzymes and HSDs are displayed in Figure 3. 
In general, exogenous androgenic steroids undergo a comparable metabolism to endogenous 
steroids. 
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Figure 3: Possible phase I androgen metabolizations exemplarily displayed on testosterone (adapted from [6]). 
Blue arrows indicating modifications mainly catalysed by CYP-enzymes; green arrows indicating modifications 
mainly catalysed by HSDs. -OH corresponds to possible hydroxylation, -oxo corresponds to oxo-functionalization 
Metabolization by HSDs is of paramount importance for metabolism of endogenous anabolic 
androgenic steroids (EAAS). eir simplified metabolic pathway is displayed in Figure 4. Focus is 
laid on steroids playing a key role in anti-doping analysis (discussed in Chapter 2.3) and also in 
this work (Manuscript III and Manuscript IV). 
 
Figure 4: Metabolism of endogenous anabolic androgenic steroids (EAAS) with focus on steroids relevant for 
anti-doping analysis: androstenedione (AED, 7), testosterone (T, 9) and 5α-dihydrotestosterone (5αDHT, 10), 5α-
androstanediol (5αAdiol, 14), androsterone (A, 15), 5α-androstanedione (5αAD, 16), 5β-dihydrotestosterone 
(5βDHT, 17), 5β-androstanediol (5βAdiol, 18), etiocholanolone (Etio, 19) and 5β-androstanedione (5βAD, 20); 
with corresponding enzymes indicated next to the arrows 
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e male sex hormone testosterone (9) is synthesized from its prohormone androstenedione (7) 
and is reduced either by 5α-reductase (mainly located in the endoplasmatic reticulum) or 5β-
reductase (mainly located in the cytoplasm) to the corresponding dihydrotestosterone (10 or 17). 
Like a majority of other enzymes, 5α- or 5β-reductases, which play an important role in the 
biosynthesis of steroids, are not only able to metabolize endogenous steroids but xenobiotics, as 
well. e structure of the parent steroid herein influences the extend of 5α- or 5β-steroid-
formation [12]. 
2.1.2 Endocrine disruptors 
Endocrine disruptors (EDs) are exogenous substances interfering with the endocrine 
system [13]. ey increase the risk of health-related problems (e.g. cancer, metabolic diseases and 
reproductive impairment) by altering processes involved in the regulation of hormone balance. 
Exposure with EDs occurs through deliberately or unnoticed contact with these substances in 
ultimately every situation of daily life. Some examples are the intake over food, pharmaceuticals 
or drinking water but also leached substances from plastic wrappings or boles, ingredients of 
cosmetics and personal care products or toys. As the endocrine system is very complex and 
hormones act in extremely low concentrations, interfering effects are likely. In an expert consensus 
statement published in January 2020, La Merrill et al. describe 10 key characteristics of EDs [14]. 
e key characteristics describe points in hormonal generation and their action, where EDs can 
interfere. One of these key characteristics, which is particularly relevant for metabolism, is the 
process of “hormone breakdown and clearance”. It is characterized by the interference of EDs with 
metabolic enzymes or mechanisms which play a role in the clearance of hormones in the body. If 
these processes are inhibited or induced, hormone concentrations are possibly altered and hence 
their effects in the human body may be changed. As endogenous steroids undergo extensive 
metabolism, interferences are likely and need further investigation. 
Non-steroidal anti-inflammatory drugs as endocrine disruptors 
Non-steroidal anti-inflammatory drugs (NSAIDs) have anti-inflammatory, analgetic and mostly 
anti-pyretic pharmacological effects. eir main therapeutic applications are hence, relieving of 
mild to moderate pain and inflammatory degenerative diseases like rheumatism or arthrosis. In 
lower doses (100 mg/day) the NSAID acetylsalicylic acid is also indicated as platelet aggregation 
inhibitor. eir mode of action can be explained through interference with the prostaglandin 
synthesis over an inhibition of the cyclooxygenase (COX). While their therapeutic effects as pain 
killers can be explained through the inhibition of COX2, several adverse drug reactions may mainly 
be explained by the simultaneous inhibition of COX1 [5]. 
According to the “Barmer Arzneimielreport 2020” ibuprofen was the drug prescribed to most 
patients assured at Barmer health insurance in Germany (Figure 5) [15]. Together with diclofenac 
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and acetylsalicylic acid there are three NASIDs in the Top 20 drugs prescribed among the assured. 
In addition, several NSAIDs are available as over the counter (OTC) drugs without prescription in 
Germany. Hence, it can be assumed that NSAIDs are the most frequently used drugs in the German 
population. A similar picture is expected for other European and international countries. 
It had been demonstrated by several publications that selected substances from the class of 
NSAIDs show endocrine disrupting effects in different experimental seings [16-23]. ese 
findings are also supported by a publication from Kristensen et al. which evaluates the fact that 
“many putative endocrine disruptors inhibit the prostaglandin synthesis” [24]. 
Due to their high usage rate and above-mentioned findings from literature, further 
investigations on the endocrine disrupting potential of NSAIDs and a subsequent re-evaluation of 
their risk profile may be reasonable. 
 
Figure 5: Top 20 prescribed drugs among BARMER assured in 2019 adapted from [15]. 
PPI: proton pump inhibitor, NSAID: non-steroidal anti-inflamatory drug; AT1: angiotensin II receptor subtype 1; 
CCB: calcium channel blocker; ACE: angiotensin-converting-enzyme; ASS: acetylsalicylic acid 
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2.2 Metabolic studies 
Most anabolic androgenic steroids are metabolized completely in humans and lile or no parent 
compound is detectable in urine, used as analytical matrix in doping control analysis (as discussed 
in Chapter 2.3). us, metabolic studies are important to identify these metabolites and to uncover 
their formation routes. is knowledge builds the basis for the development of reliable methods to 
detect and analyse steroids and their metabolites in biological samples [25] 
Generally, an evaluation of metabolic processes in humans would be the most enlightening 
method. However, in anti-doping research, as also for the general field of (forensic) toxicology 
there are some concerns of metabolic studies in humans. First, the substances themselves are toxic 
and there are ethical concerns to administer them to a large population of healthy volunteers. is 
aspect becomes even more relevant for multiple or higher doses applied, which is usually practiced 
by athletes using performance enhancing substances. In addition, the aspect of multiple drug 
administration plays an important role in anti-doping research [26, 27]. Hence, in vitro and in silico 
studies gain more and more importance in anti-doping research [28]. ey can provide a solid and 
very valuable knowledge basis to plan and perform potential subsequent administration trials. 
Unfortunately, every model aiming to reproduce human metabolic processes has its drawbacks, 
which is why their strengths and weaknesses are crucial to consider for data evaluation. 
is chapter is giving some background information on possibilities to perform metabolic 
studies with special focus on in vitro and in vivo methods relevant in this work. 
2.2.1 In vivo studies on metabolism 
As already mentioned, the most conclusive approach for metabolic studies would be the 
administration of larger amounts of substances to volunteers, followed by subsequent evaluation 
of excreted compounds. If metabolism of endogenous substances is of interest, the application of 
radiolabelled substances or substances labelled with stable isotopes with subsequent analysis of the 
matrix of interest, can be helpful to evaluate the whole metabolic profile [29]. Even if in vivo 
application trials were performed in the early years of doping control analysis and are still 
practiced today [9, 11, 25, 30-35], they may raise some critical aspects which should be assessed 
carefully. Nowadays the WADA research ethics policy, which is applied for all research projects 
founded by WADA, requests an adequate ethics review for all submied research proposals [36]. 
e adherence to the Helsinki Declaration, which is issued by the World Medical Association 
(WMA) as a statement of ethical principles for medical research involving human subjects [37], is 
recommended by WADA for “research with international scope” in anti-doping research [36]. 
However, there are some concerns on applying this declaration in anti-doping research [38]. One 
example for a critical aspect discussed by Sanchini et al. is the fact that the risk of some doping 
agents (e.g. designer steroids) is not known or even worse, known to be harmful. Nonetheless, their 
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metabolism is still important to investigate as athletes are using these compounds. erefore, 
further investigations on ethics in anti-doping research are necessary, as discussed by Sanchini et 
al. Today, application of drugs to a small group of mostly male and healthy volunteers and retro 
perspective studies are of relevance in the field. 
Application trials on small groups of volunteers are raising two further considerations. First, 
application trials mostly include only male volunteers, which leaves the question open if and how 
metabolism would differ in females. Second, trials are performed on small groups of volunteers or 
even just individual persons. is is on the one hand reasonable due to the potential low or missing 
information on the health risk of the drug, but on the other hand this study design causes the 
question of transferability of the results to a larger population. It is known, that the extend of 
metabolism varies with e.g. age, sex, ethnicity or genetic variations. Furthermore, exogenous 
factors (e.g. medication, training, consumption of food or dietary supplements) can influence 
reactions involved in the metabolism. Hence, the excretion and subsequent detection of metabolites 
can be influenced [39, 40]. e influenceability of metabolic processes is also discussed in more 
detail in Chapter 2.3.4. Due to these individual variations and the influenceability through 
exogenous factors, the interpretation of metabolic studies and extrapolation to a large population 
is challenging and needs very careful evaluation of data. 
As mentioned above, detection of new metabolites can also be achieved in retro perspective 
studies by re-evaluation of already tested samples [41, 42] or from samples collected during 
observation studies on patients or persons using the compounds of interest [43]. is type of study 
is giving the opportunity to predefine samples of a specific population (e.g. ethnicity, sex, age). It 
is furthermore possible to evaluate a rather big number of samples, which do not need to be 
“generated” from the scratch. Generally, results from retro perspective studies should be treated 
carefully. is is especially important if samples from uncontrolled trials or patient samples are 
used. In this case only limited information may be available on the background of the samples. 
Some factors which may be unknown, but which are relevant for the interpretation of metabolic 
profiles are concurrent medication of patients, age, sex or dietary habits (Chapter 2.3.4). Another 
critical point of retro perspective studies is related to samples deriving from an existing sample 
previously tested positive for a certain compound. Re-evaluation of this sample may reveal 
misleading results as the metabolites detected may have another origin than the compound they 
were originally declared as positive for. Hence, evaluation of samples from retro perspective 
studies shall be performed very carefully and as much as possible background information should 
be gathered to draw conclusions as precise as possible. 
In addition to application trials or retro perspective evaluations on humans the picture of in 
vivo methods shall be concluded by animal experiments. Animal models are mainly used in the 
early drug development and in toxicological studies to gain data on chemical and metabolic 
properties and potential risks of a substance, before proceeding with clinical trials on humans.  
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In anti-doping research there are for example animal studies using baboons [44, 45], rats [46] 
or zebrafish [47]. All of them having advantages and disadvantages. e difficulty with animal 
models is, among others, the requirement of an approval from an animal welfare commiee and 
the transferability to humans. Enzymes and non-enzymatic processes involved in 
biotransformation (e.g. gut metabolome, transport mechanisms, binding of metabolites and 
excretion mechanisms) in animal models may differ from these in humans. ey hence possibly 
lead to divergent findings [48]. In addition to the already mentioned methods, there are studies on 
chimeric animals, which can be a promising tool, but still show differences to known human 
metabolic profiles [49, 50]. In conclusion every (animal) model remains a model and it is important 
to know the strengths and limitations of this model and to not generalize made findings. 
Due to the oen-unsatisfying transferability of animal studies to humans and to preserve the 
animal wellbeing, several research societies, organisations and researchers work on so called 3R 
(Reduce, Replace, Refine) methods. is is also regulated by the directive 2010/63/EU of the 
European Parliament and of the Council of 22 September 2010 on the protection of animals used 
for scientific purposes [51]. e goal of 3R method development is to Reduce the number of animals 
per test to a minimum while obtaining the same amount of information; Replace as many animal 
tests as possible with other methods (e.g. in vitro or in silico) and Refine those tests which cannot 
be replaced, to guarantee the animal welfare. e Organisation for Economic Co-operation and 
Development (OECD) as international institution and the European Union Reference Laboratory 
for alternatives to animal testing (EURL ECVAM) as part of the Joint Research Centre (JRC) of the 
European Commission are just two organizations engaging in this field. is movement is 
especially important in the field of pharmacology and toxicology and early drug development but 
may also be transferred to metabolic studies in the field of anti-doping research and other areas. 
2.2.2 In vitro studies on metabolism 
Human trials may raise multiple concerns mentioned above and animal models oen have 
ethical concerns while potentially not leading to completely satisfying results in terms of 
comparability to humans. Hence in vitro studies are a cost efficient and convenient method to 
collect information about metabolism. 
Not only in doping control analysis important in vitro models for the analysis of metabolism 
are recombinant human enzymes or liver preparations, as enzymatic concentrations are especially 
high in this organ [29, 52]. 
• Hepatocytes are cells deriving from the liver. ey are available as primary hepatocytes 
isolated directly from the liver or as tumour cell-lines with the advantage of self-renewal 
and longer life than primary cells. Tumour cell-lines have the disadvantage of lower 
metabolic activities (especially when number of performed passages is high) and hence 
minor or even no suitability for metabolic studies. Hepatocytes can also be cultivated in 
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3D-cell cultures as spheroids, organoids or even in multi-organ models to study the 
influence of surrounding tissues. 
• Human liver microsomes (HLM): “Artefactual spherical particles, not present in the 
living cell, derived from pieces of the endoplasmic reticulum present in homogenates of 
tissues or cells” [53]. ey sediment from S9-fraction and are oen used as a source of 
membrane bound monooxygenase enzymes, 
• S9-fraction: “Supernatant fraction obtained from an organ (usually liver) homogenate by 
centrifuging at 9000 g for 20 min in a suitable medium” [53]. e S9-fraction contains 
enzymes in lower concentrations compared to HLMs leading to generally lower turnover 
rates. Due to the presence of microsomal as well as cytosolic proteins the whole metabolic 
profile can be observed [29]. 
• Recombinant human enzymes are available either as isolated preparations or as 
recombinantly expressed proteins in host cells. 
As isolated recombinant human enzymes and Schizosaccharomyces pombe (S.pombe) strains 
recombinantly expressing human CYP-enzymes and are mainly used in this work to study steroid 
metabolism, these two models are described in more detail. 
Recombinant enzymes expressed in Schizosaccharomyces pombe as 
metabolic catalyst 
S.pombe is well suited to be used as a host for the expression of functional human enzymes [54]. 
Whole cell biotransformations using S.pombe strains were performed using genetically modified 
fission yeast strains provided by the group of Prof. Dr. Mahias Bureik (School of Pharmaceutical 
Science and Technology, Tianjin University, China). e approach is quite straightforward: fission 
yeast cells recombinantly expressing the enzyme of interest are cultivated and the substrate in 
question is added. Aer an appropriate incubation time reaction products are isolated from the 
incubation broth and subsequently analysed and/or identified. 
In this work whole cell biotransformation assays with S.pombe strains, recombinantly 
expressing human CYPs were used to evaluate metabolic products and to generate minor amounts 
of metabolites [55, 56]. Besides the chemical synthesis of metabolites as reference material also the 
biotechnological production (e.g. using S.pombe) or a combination of both approaches plays a role 
and has been performed successfully in the past [9, 54, 57-59]. e generation and availability of 
reference substances is a crucial topic as it is sometimes very difficult to acquire suitable material. 
Nonetheless, accurate quantitative analysis and unambiguous metabolite identification in proper 
samples can only be performed, when reference compounds are available [60]. 
Besides performing whole cell biotransformations, the group of Prof. Dr. Bureik developed an 
assay using permeabilized fission yeast (so called enzyme bags) to study metabolism [56, 61]. Some 
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major advantages and disadvantages and main application areas of whole cell biotransformation 
assays and enzyme bags compared to isolated recombinant human enzymes are listed in Table 2. 
Isolated recombinant enzymes for metabolic studies 
Rosano and Ceccarelli state in their review article: “At the theoretical level, the steps needed for 
obtaining a recombinant protein are prey straightforward. You take your gene of interest, clone 
it in whatever expression vector you have at your disposal, transform it into the host of choice, 
induce and then, the protein is ready for purification and characterization. In practice, however, 
dozens of things can go wrong” [62]. is describes the basic steps and already mentions some 
difficulties in recombinant enzyme production. As the purpose of this work is the use of 
recombinant human enzymes and not their production, preparation shall not be commented in 
more detail here. Nonetheless, this quote is mentioning the three major steps of enzyme 
production: expression, isolation and purification. ese stages also play a role e.g. in the quality 
assessment of an enzymatic preparation, which is crucial for metabolic experiments. 
For metabolic studies it is important that the enzyme of interest is functional, meaning it 
catalyses the desired reaction; pure, meaning the preparation only contains the desired protein and 
that it is soluble in the assay system and the storage buffer. For the presented work commercial 
enzymatic preparations were used. e functional quality of these commercially available 
preparations can be estimated from the accompanying data sheet. e actual functionality can for 
example be evaluated by incubation of the enzyme with a well characterized substrate and the 
evaluation of the product(s) formed. Cytosolic and small enzymes (< 60 kDa) are generally easier 
to produce than membrane bound or large enzymes (> 60 kDa) [62]. In general, metabolic studies 
using isolated recombinant enzymes are a convenient method, as they are relatively easy in 
handling compared to all other methods described above. A detailed overview of advantages and 
drawbacks and some main application areas are reported in Table 2. 
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Table 2: Comparison between S.pombe based whole-cell biotransformation assays (whole-cell BT), enzyme bag 
assays and isolated recombinant human enzymes (Iso rh enzymes) for metabolic studies with main application 
areas relevant for this work 
 Whole-cell BT Enzyme bag Iso rh enzymes 
Main application area Production of reference 
material 
Metabolic studies with 
subsequent product 
characterization 
(several mg of substance 
needed) 
Evaluation of metabolic 
routes 
Evaluation of metabolic 
routes and kinetic 
characterization of 
enzymes 
Advantages Product-generation in 
mg-scale (production of 
reference material) 
No addition of co-factor 
needed (if 
corresponding gene is 
co-expressed in yeast) 
Regrowing 
(cost efficient) 
Enzymes are membrane 
bound (no modification 
or tag needed for 
isolation or purification) 
 
Faster compared to 
whole-cell BT 
 






Enzymes are membrane 
bound (no modification 
or tag needed for 
isolation or purification) 
 
Fast from experiment to 
result 
 
Low substrate amounts 
needed 
 
Disadvantages Substrate (and product) 




needed (µg-mg range) 
Longer incubation times 
compared to enzyme 
bags and iso rh enzymes 
Need to grow cells 
before assay 
Addition of co-factor 
necessary (needs to be 
purchased) 
Need to grow cells 
before assay 
Addition of co-factor 
necessary (needs to be 
purchased) 
Enzyme must be 
purchased if not 
produced in-house 
(which is currently not 
the case for us) 
Modifications and/or 
tags needed for isolation 
from host, purification 
or stabilization in 
solution (missing or 
additional amino acids 
in protein)  no “wild-
type” enzyme 
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2.2.3 In silico studies on metabolism 
is chapter very briefly mentions the third pillar of metabolic studies. Besides in vivo and in 
vitro studies in silico experiments are of relevance in the context of metabolic studies. e term “in 
silico” captures approaches developed to estimate an experimental outcome with the help of 
mathematical models and computer simulations. One example are molecular modelling 
experiments which were performed by Alexanda Naß from the group of Prof. Dr. Gerhard Wolber 
in the context of Manuscript I and by David Machalz also from the group of Prof. Dr. Wolber for 
Manuscript II. Besides other in silico methods, which shall not be discussed in more detail, docking 
experiments can help to beer understand mechanisms and specific sequences of metabolic 
processes. With 3D-visualization of enzymatic structures, substrates, co-factors and inhibitors it is 
possible to, among other things, beer explain and interpret results obtained during in vitro and in 
vivo experiments. 
2.3 Doping control analysis 
“e purposes of the World Anti-Doping Code and the World Anti-Doping Program which 
supports it are: 
• To protect the Athletes’ fundamental right to participate in doping-free sport and thus 
promote health, fairness and equality for Athletes worldwide, and 
• To ensure harmonized, coordinated and effective anti-doping programs at the international 
and national level with regard to detection, deterrence and prevention of doping” [63]. 
To assure that these intentions of the “World Anti-Doping Code” can be met, doping control 
analysis performed by anti-doping laboratories plays a central role. Besides the superordinated 
“World Anti-Doping Code”, the International Standard for Laboratories (ISL), one of several 
International Standards published by WADA, describes regulations and procedures important for 
anti-doping laboratories [64]. An example for regulations described in the ISL are the technical 
documents (TD) which regulate procedures for the analysis of prohibited substances. TDs relevant 
for the detection of AAS are mentioned in more detail in Chapter 2.3.2. 
is chapter is giving a short introduction on doping control analysis and how doping control 
is performed and organized nowadays. A simplified testing process with focus on analysis of urine 
samples according to the International Standard for Testing and Investigations (ISTI) is depicted in 
Figure 6 [65]. A key goal of the whole testing process should be to declare as less as possible 
samples as false negative, meaning an athlete doped but doping is not detected and even more 
important do not produce false positive testing results, meaning an athlete has not doped but the 
result of analysis reported an adverse analytical finding (AAF). 
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Figure 6: Simplified testing process of anti-doping samples: Testing authority (TA) selects athlete to be tested; 
athlete provides urine (and/or blood) sample, divides it into A- and B-sample and fills accompanying form; one 
copy of this form is send to each the athlete and TA and one anonymized form (including: sample-code, sport-
discipline, measured specific gravity and any medication taken) and the A- and B-samples are send to the 
laboratory; laboratory performs analysis (screening and possibly confirmation) on the A-sample according to the 
flowchart and reports the results to TA. In case of an AAF, athlete has the right to request supervised analysis of 
B-sample [65] 
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2.3.1 World Anti-Doping Agency and the Prohibited List 
“e Code is the fundamental and universal document upon which the World Anti-Doping 
Program in sport is based” [63]. It regulates all fields connected to anti-doping with the goal to 
“keep the spirit of sport” and hence to minimize doping in sport, which “is fundamentally contrary 
to the spirit of sport” [63]. is includes, but is not limited to, doping control, education and 
research in the field of doping and its prevention. e WADA Prohibited List regulates all 
substances and methods which are regarded as doping and hence prohibited and controlled [66]. 
e Prohibited List is divided in three sections: 
• substances and methods prohibited at all times (in and out of competition) including 
◦ substance categories: S0 non-approved substances; S1 anabolic agents; S2 peptide 
hormones, growth factors, related substances and mimetics; S3 beta-2-agonists; S4 
hormone and metabolic modulators; S5 diuretics and masking agents and 
◦ methods: M1 manipulation of blood and blood components; M2 chemical and physical 
manipulation and M3 gene and cell doping, 
• substances and methods prohibited in-competition including 
◦ substance categories: S6 stimulants; S7 narcotics; S8 cannabinoids and S9 glucocorticoids 
and 
• substances prohibited in particular sports 
◦ class P1 beta-blockers. 
In addition to this list, the monitoring list contains “substances which are not on the Prohibited 
List, but which WADA wishes to monitor in order to detect paerns of misuse in sport” [67]. 
is work is focussing on the metabolism of AAS and its influenceability by non-prohibited 
drugs. Hence, class S1 of the Prohibited List plays an outstanding role. is class includes AAS and 
“other anabolic substances” and lists substances, which are prohibited when administered 
exogenously. Furthermore the number of prohibited compounds is extended by “other substances 
with a similar chemical structure or similar biological effect(s)” [66] to also include potentially new 
structures and so called “designer-steroids”. 
2.3.2 Steroid determination in anti-doping analysis 
Since the Olympic games in Los Angeles in 1984 gas chromatography coupled to mass 
spectrometry (GC-MS) is used for AAS detection in anti-doping analysis [68]. Due to the poor 
ionization of the majority of AAS and their metabolites in liquid chromatography (LC), GC is the 
method of choice to detect unconjugated steroids. Currently, routine protocols for anti-doping tests 
determine steroid concentrations as combined free (unconjugated) and glucuronide fraction. 
Analysis is generally done aer hydrolysis of glucuronide conjugates in the urine samples using 
β-glucuronidase. Aer liquid-liquid extraction of free steroids and the cleaved aglycons, 
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trimethylsilyl-derivatization is generally performed using a mixture of N-methyl-N-
(trimethylsilyl)-trifluoroacetamide (MSTFA), ammonium iodide (NH4I) and ethanethiol or 
mercaptoethanol [3, 69]. e trimethylsilylation of polar hydroxy- and oxo groups leads to the 
formation of the corresponding ethers or enol-ethers which allows for more sensitive detection of 
the analytes [70]. For oxo-groups it is mentionable that derivatization isomers may be formed, 
which usually appear as distinct peaks in the chromatogram. 
e analysis and detection of AAS is performed by WADA accredited laboratories according to 
the technical documents provided by WADA [71], mainly the following: 
• TD2018EAAS (“Endogenous Anabolic Androgenic Steroids - Measurement and 
Reporting”) for the detection of most pseudo-endogenous and synthetic steroids [3], 
• TD2019IRMS (“Detection of Synthetic forms of Endogenous Anabolic Androgenic Steroids 
by GC-C-IRMS”) for confirmation analysis via gas chromatography-combustion-isotope 
ratio mass spectrometry [72] and 
• TD2019NA (“Harmonization of Analysis and Reporting of 19-Norsteroids Related to 
Nandrolone”) for the “confirmation procedure for the analysis and reporting of findings 
for 19-norsteroids related to nandrolone” [73]. 
In case of administration of pseudo-endogenous AAS, meaning steroids, which are identical to 
endogenously occurring steroids (e.g. exogenous testosterone), or long-term administration of 
synthetic AAS selected concentrations of EAAS and concentration ratios are altered. Consequently, 
these concentrations and concentration ratios of EAAS are determined following the technical 
document TD2018EAAS [3]. is is usually done by gas chromatography coupled to triple 
quadrupole mass spectrometers (GC-QQQ). For years fixed limits of steroid ratios, based on 
population-based reference values, were used to classify a specific result as an AAF, meaning a 
positive testing result. Over the years it had been found that individual limits show more accurate 
results as for example individual enzymatic variations may alter e.g. the T/E ratio to “untypical” 
low or “untypical” high values [74]. As it was found that specific concentration ratios of EAAS are 
stable over months and even years in individuals [75-78], WADA initiated the athlete biological 
passport (ABP) steroidal module in 2014 [79]. Additionally, to detect the administration of 
synthetic steroids, precursors and reported (long-term) metabolites are monitored. A 
comprehensive overview of long-term metabolites used for the detection of synthetic steroids in 
the Cologne anti-doping laboratory is given by Geyer et al. [80]. 
Besides the screening procedures predominantly using Gas chromatography-tandem mass 
spectrometry (GC-MS/MS) instrumentation, a confirmation analysis using gas chromatography 
combustion isotope ratio mass spectrometry (GC-C-IRMS) is performed in case of a positive 
screening result for EAAS (Figure 6). is method is able to discriminate between endogenous and 
exogenous steroids by measuring the ratio of the stable isotopes 13C and 12C [81-83]. In case of a 
26  eoretical Background 
positive testing in the screening for synthetic steroids a confirmation using GC-MS/MS is 
performed. 
Despite the predominance of GC-MS analysis in steroid detection, liquid chromatography 
coupled to mass spectrometry (LC-MS) builds a powerful technique for analytes showing poor 
chromatographic behaviour in GC or those causing problems during derivatization [68]. 
Furthermore, several studies had been published on the detection of intact phase II steroid 
metabolites (glucuronides and/or sulphates) using GC-MS(/MS) or LC-MS(/MS) [84-87]. e 
detection of phase II metabolites may be of interest to extend the detection window of steroid 
metabolites. 
A further perspective is use of high-resolution mass spectrometry (HRMS). HRMS 
measurements enable the tentative detection of potential new designer steroids or new metabolites 
of already known substances through accurate mass measurements. An example for HRMS is the 
use of gas chromatography coupled to time-of-flight mass spectrometry (GC-q-ToF) as a screening 
application [88]. e operation of this instrument in full scan mode may open the opportunity of 
retro perspective analysis for additional compounds of already analysed samples. is is not 
possible with QQQ data, as only preselected ion-transition and hence only preselected analytes are 
considered. 
2.3.3 Athlete Biological Passport 
e athlete biological passport (ABP) is a tool to monitor longitudinal changes of each individual 
athlete in anti-doping testing. Already in 2009, the haematological module has been implemented 
in the ABP, in 2014 the steroidal module followed. An additional endocrinological module is in 
preparation and in future also a forensic module and a performance module may be planned [89]. 
e focus of this chapter is on the steroidal module of the ABP. Its goal is the detection of EAAS 
administration and long-time use of synthetic AAS, which are resulting in alterations of the 
monitored markers in the ABP. e steroidal module currently includes six endogenous steroid 
concentrations (T, E, A, Etio, 5αAdiol and 5βAdiol) and five ratios of EAAS-concentrations (T/E, 
A/T, A/Etio, 5αAdiol/5βAdiol and 5αAdiol/E). e concentrations are measured by WADA-
accredited laboratories according to the WADA technical document TD2018EAAS in urine samples 
collected from the athletes in and out of competition [3]. Following the WADA Athlete Biological 
Passport Operating Guidelines, all measured concentrations and concentration ratios shall be 
reported in the ABP module of the Anti-Doping Administration and Management System 
(ADAMS) [79]. is module automatically applies an “adaptive model” on all entries for this 
specific athlete (starting at the addition of the third sample) [74]. Individual limits are determined 
for each athlete and upon each new reporting by applying a Bayesian fit to the datapoints [90]. 
Based on these results, the sample is declared as negative, as adverse passport finding (APF) or as 
suspicious steroid profile (SSP) and further steps are initiated as depicted in Figure 6. In addition 
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to the screening analysis and if needed the confirmation analysis, the laboratory shall confirm the 
presence of confounding factors (Chapter 2.3.4) [3]. If the screening results are confirmed in the 
confirmation method, the B-sample may be analysed. For this procedure, the athlete or his/her 
representative is allowed to aend the analysis in the laboratory. Only in the case of a confirmation 
of the positive findings from the A-sample, a positive testing result is reported. 
2.3.4 Factors influencing the steroid profile 
Especially the ratios, which are part of the steroidal module of the ABP, haven been shown to 
be very stable in individual adult humans [75-78]. Nonetheless, the steroid metabolism in humans 
is very complex and many enzymes are involved. Consequently, influencing of these enzymatic 
processes might change the metabolism and hence the excretion of EAAS and the steroidal profile. 
Marck-Engelke et al. did a lot of research on the stability of steroid profiles in males and females 
and described various factors influencing the steroid profile [76-78, 91, 92]. It is important to 
perform these investigations in males as well as in females, as metabolic routes and hence steroidal 
profiles differ in males and females. As concentrations of EAAS in females are much lower than in 
males [3], the detection requires very sensitive methods and hence, interpretation of steroid 
profiles especially in females is challenging [78, 92-94]. In general, changes in steroid profile 
markers induced by endogenous factors shall be covered by the use of the ABP steroidal module. 
A collection of some examples for endogenous factors possibly influencing the steroid profile in a 
general or more individual manner are listed hereaer: 
• Sex, age, genetic polymorphisms and ethnicity (among which similar genetic variations are 
oen observable) [40, 75, 93, 95-97], 
• Menstrual cycle (discussed contrarily) [78, 94, 98, 99], and 
• Time during day [78, 98]. 
In addition to interindividual variations in the steroid profile caused by endogenous factors, 
there are some exogenous aspects able to influence the steroid profile [100]: 
• Pregnancy or administration of human chorionic gonadotropin (hCG) in males (and 
females), 
• Psychological effects like stress (e.g. in and out of competition testing; or testing aer a 
victory or a loss) are still discussed contrarily [101-103], and 
• Intake of (non-prohibited) drugs; including, but not limited to [3]: 
◦ Oral contraceptives [91, 98], ethanol [104], antifungals [105-107], aromatase-inhibitors, 
antiestrogens and 5α-reductase inhibitors, other AAS, masking agents (e.g. probenecid) 
or diuretics. 
Besides these personal factors there are also analytical factors like bacterial contamination, 
hydrolysis, coelution and matrix effects, which can confound the steroidal profile and hence the 
detection of AAS [100]. 
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As these confounding factors can lead to significant changes in the steroid profiles and to 
divergent testing results during an anti-doping test, the presence of already known confounding 
factors should be monitored during an anti-doping analysis [3]. To consistently improve the 
analytical performance, it is furthermore of relevance to additionally keep investigating the 
potential of other substances acting as confounding factors. 
e knowledge of substances interfering with the steroid metabolism may help to beer 
interpret anti-doping testing results and hence reduce the number of false negative and even more 
important, false positive testing results. 
In addition to the relevance in the field of anti-doping research, the knowledge of compounds 
interfering with steroid metabolism may be of value in the detection and investigation of potential 
endocrine disrupting substances (Chapter 2.1.2) and hormone related disorders. 
Non-steroidal anti-inflammatory drugs and doping 
Until now NSAIDs are neither included in the WADA Prohibited List, nor in the list of 
confounding factors monitored by anti-doping laboratories. However, just recently a German TV-
documentary with special focus on the use of NSAIDs in soccer players came out [108]. e 
documentary describes the extensive use of pain killers among soccer players at all performance 
levels. Finally, the justification of extensive NSAID use in sports is discussed. e WADA Anti-
Doping Code states that a substance which meets at least two of the following points shall be 
considered for inclusion to the Prohibited List [63]: 
• Potential to enhance or enhancement of sport performance, 
• Actual or potential health risk to the athlete or 
• Use violates the spirit of sport. 
In the documentary Hans Geyer from the Cologne anti-doping laboratory argues, that in the 
case of NSAIDs all three of these points are met. 
e fact that NSAIDs are the most commonly used drugs in sports has been known for years [26, 
27, 109-111]. In addition, it was shown in vitro, that the NSAIDs ibuprofen and indomethacin inhibit 
the enzymes AKR1C2 and AKR1C3, which play an important role in the metabolism of EAAS 
(Chapter 2.1.1) [112-114]. In consequence, an influence of the intake of indomethacin or ibuprofen 
on the steroid profile was thinkable. Results of investigations on this are presented in 
Manuscript III and in Manuscript IV and are discussed in Chapter 5. 
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3 MANUSCRIPTS 
3.1 Manuscript I: “Combined chemical and biotechnological 
production of 20βOH-NorDHCMT, a long-term 
metabolite of Oral-Turinabol (DHCMT)” 
Jiaxin Liu, Lei Chen, Jan Felix Joseph, Alexandra Naß, Anna Stoll, Xavier de la Torre, Francesco 
Botrè, Gerhard Wolber, Maria Kristina Parr and Mahias Bureik 
 
Journal of Inorganic Biochemistry; 183 (2018) 165-171 
hps://doi.org/10.1016/j.jinorgbio.2018.02.020 
 
Abstract: Anabolic androgenic steroids (AAS) are misused very frequently in sport 
competitions as performance enhancing agents. One of the doping compounds that has been 
detected with increased frequency in the last few years is dehydrochloromethyltestosterone 
(DHCMT, 4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-one; brand name Oral 
Turinabol). e long-term DHCMT metabolite 20βOH-NorDHCMT (4-chloro-17β-hydroxymethyl-
17α-methyl-18-norandrosta-1,4,13-trien-3-one) was reported earlier to be detectable in urine 
samples for more than 22 days aer DHCMT administration; however, purified reference material 
was not available so far. In this study we demonstrate a successful combination of Wagner-
Meerwein rearrangement of DHCMT to NorDHCMT (4-chloro-17,17-dimethyl-18-norandrosta-
1,4,13-trien-3-one) and subsequent whole-cell biotransformation with a recombinant fission yeast 
strain expressing the human cytochrome P450 enzyme (CYP or P450) CYP21A2 for the synthesis 
of mg amounts of this metabolite. It was then used as reference for the analysis of a post 
administration urine of DHCMT. e availability of this reference compound will provide an 
incontestable proof for DHCMT abuse. 
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3.2 Manuscript II: “Fine-mapping of the substrate 
specificity of human steroid 21-hydroxylase (CYP21A2)” 
Anna Stoll, Steffen Loke, Jan Felix Joseph, David Machalz, Xavier de la Torre, Francesco Botrè, 
Gerhard Wolber, Mahias Bureik and Maria Kristina Parr 
 
Journal of Steroid Biochemistry and Molecular Biology; 194 (2019) 105446 
hps://doi.org/10.1016/j.jsbmb.2019.105446 
 
Abstract: Cytochrome P450 enzymes (CYPs) are capable of catalysing regio- and stereo-specific 
oxy functionalization reactions, which otherwise are major challenges in organic chemistry. In 
order to make the best possible use of these biocatalysts it is imperative to understand their 
specificities. Human CYP21A2 (steroid 21-hydroxylase) acts on the sidechain aached to C-17 in 
ring D of a steroid substrate, but the configuration of ring A also plays a prominent role in substrate 
cognition. Here, we comprehensively investigated this relationship using sixteen 17,17-dimethyl-
18-nor-13-ene steroids with different arrangements of hydroxy-, oxo-, fluoro- and chloro-groups 
and in the presence or absence of double bonds (Δ1 and/or Δ4) and heteroatoms in ring A. e 
results show that presence of a 3-oxo group is a strict requirement for a CYP21A2 substrate, while 
the other configurations tested were all tolerated. is was also confirmed by control experiments 
using endogenous steroids. While progesterone and 17-hydroxyprogesterone were hydroxylated 
at C-21, (17-hydroxy-) pregnenolone did not react. Molecular docking experiments indicate that 
the interaction of the carbonyl group at C-3 to the sidechain Arg234 of the enzyme is indispensable. 
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3.3 Manuscript III: “Influence of Pain Killers on the Urinary 
Anabolic Steroid Profile” 
Anna Stoll, Michele Iannone, Giuseppina De Gregorio, Xavier de la Torre, Francesco Molaioni, 
Francesco Botrè and Maria Kristina Parr 
 
Journal of Analytical Toxicology; 44 (2020) 871-879 
hps://doi.org/10.1093/jat/bkaa049 
 
Abstract: Anabolic androgenic steroids (AAS) are prohibited as performance-enhancing drugs 
in sports. Among them, testosterone and its precursors are oen referred to as “pseudo 
endogenous” AAS, that is, endogenous steroids that are prohibited when administered 
exogenously. To detect their misuse, among other methods, the World Anti-Doping Agency-
accredited laboratories monitor the steroid profile (concentrations and concentration ratios of 
endogenous steroids, precursors and metabolites) in urine samples collected from athletes in and 
out of competition. Alterations in steroid profile markers are used as indicators for misuse of 
anabolic steroids in sports. erefore, especially their metabolic pathways with possible 
interactions are crucial to elucidate. As steroid metabolism is very complex and many enzymes are 
involved, certain non-prohibited drugs may influence steroid metabolite excretion. One important 
group of steroid-metabolizing enzymes is aldo–keto reductases (AKRs). An inhibition of them by 
non-steroidal anti-inflammatory drugs (NSAIDs), which are neither prohibited nor monitored, but 
frequently used drugs in sports, was demonstrated in vitro. us, this work aims to investigate the 
influence of NSAID intake on the urinary steroid profile. Kinetic and inhibitory studies were 
performed using 5α-dihydrotestosterone as substrate. e results obtained from in vitro 
experiments show that ibuprofen inhibits AKR1C2 and thus influences steroid biotransformation. 
For in vivo investigations, urine samples prior, during and post administration of ibuprofen were 
analysed using routine methods to monitor the steroid profile. Changes in markers of the steroid 
profile of volunteers were observed. e combination of in vitro and in vivo results suggests that 
monitoring of ibuprofen may be useful in doping control analysis. e presented work illustrates 
the importance to consider co-administration of (non-prohibited) drugs during anti-doping 
analysis. Intake of multiple substances is likely leading to interfering effects. Divergent results in 
anti-doping analysis may therefore be observed and misinterpretation of analytical data is likely 
to occur. Similar considerations are appropriate for other fields of forensic applications.
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Abstract: Anabolic androgenic steroids (AAS) are prohibited as doping substances in sports by the
World Anti-Doping Agency. Concentrations and concentration ratios of endogenous AAS (steroid
profile markers) in urine samples collected from athletes are used to detect their administration. Certain
(non-prohibited) drugs have been shown to influence the steroid profile and thereby sophisticate
anti-doping analysis. It was shown in vitro that the non-steroidal anti-inflammatory drug (NSAID)
indomethacin inhibits selected steroid-biotransformations catalyzed by the aldo-keto reductase
(AKR) 1C3, which plays a key role in the endogenous steroid metabolism. Kinetic parameters for
the indomethacin-mediated inhibition of the AKR1C3 catalyzed reduction in etiocholanolone were
determined in vitro using two comparing methods. As NSAIDs are very frequently used (not only)
by athletes, the inhibitory impact of indomethacin intake on the steroid metabolism was evaluated,
and steroid profile alterations were detected in vivo (one male and one female volunteer). Significant
differences between samples collected before, during or after the intake of indomethacin for selected
steroid profile markers were observed. The presented results are of relevance for the interpretation of
results from doping control analysis. Additionally, the administration of NSAIDs should be carefully
reconsidered due to their potential as endocrine disruptors.
Keywords: NSAID; inhibition; doping; aldo-keto reductases; endocrine disruption
1. Introduction
Anabolic androgenic steroids (AAS) are very frequently used drugs in sports [1]. Their use as
doping agents is prohibited in and out of competition by the World Anti-Doping Agency (WADA;
class S1 in the WADA prohibited list) [2]. The analytical detection is challenging, especially if so-called
pseudo endogenous AAS (e.g., exogenous testosterone) are used as performance enhancing substances,
due to their high similarity to the naturally occurring endogenous AAS (EAAS). To detect the misuse
of those pseudo endogenous and some synthetic AAS, anti-doping laboratories monitor in a first
step, concentrations and concentration ratios of selected EAAS according to the WADA technical
document TD2018EAAS in urine samples collected from the athletes [3]. In case of misuse of pseudo
endogenous AAS or some synthetic AAS, those steroid profile markers are altered and a confirmative
method using gas chromatography combustion isotope-ratio mass-spectrometry (GC-c-IRMS) is
Metabolites 2020, 10, 463; doi:10.3390/metabo10110463 www.mdpi.com/journal/metabolites
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applied. Since it has been shown that ratios of urinary steroids are stable over months and even
years in adult humans [4–6] but show interindividual variations, the steroidal module of the Athlete
Biological Passport (ABP) was introduced by WADA in 2014 [7]. With this longitudinal monitoring
model, it is possible to better detect intraindividual changes, and hence the potential misuse of AAS.
However, it was shown that besides various endogenous and exogenous parameters, the intake of
selected (non-prohibited) drugs can influence the individual steroid profile and lead to suspicious
testing results [8–10]. To better understand how changes in the steroid profile can occur after the
intake of specific drugs, it is helpful to understand and further investigate the steroid metabolism
and potential points of interference. One enzyme-family which plays a key role in the metabolism
of EAAS are aldo-keto-reductases (AKR; Figure 1). In this study we focused on the AKR1C3, which
is known to oxidize 17-hydroxy steroids to their corresponding 17-oxo metabolites and vice versa.
It was reported that the reduction route is favored in vivo [11]. Furthermore, it was reported by Byrns
et al. that the non-steroidal anti-inflammatory drug (NSAID) indomethacin inhibits the AKR1C3
catalyzed reduction in androst-4-ene-3,17-dione in vitro selectively over the closely related AKR1C2
and AKR1C1 [12,13]. No further investigations have been made on the inhibitory effect of indomethacin
on 5β-androstanes metabolized by AKR1C3. As NSAIDs are very frequently used drugs (not only)
among athletes [14,15], this work aims to further investigate the influence of indomethacin on the
steroid metabolism in vitro and wants to show the relevance of indomethacin on the urinary steroid
profile in vivo. Hence, the work consists of an in vitro part and an in vivo application trial. The in vitro
experiments were analyzed spectro-fluorometrically in real time and by gas chromatography coupled
to a quadrupole-time-of-flight mass spectrometer (GC-QToF) as confirmative tests. For the in vivo
part, indomethacin was administered to one male and one female volunteer in therapeutic doses
over 14 days. Urine samples before, during and after the administration were collected and analyzed.
The results first give ideas on the impact of indomethacin intake on steroid profiles in doping control
analysis and its potential mechanism of endocrine disruption.
Figure 1. Metabolism of endogenous anabolic androgenic steroids (EAAS); blue and bold: substrates
and enzymes used in this publication.
2. Results
2.1. Qualitative Incubation In Vitro
With the applied GC-MS (gas chromatography-mass spectrometry) method, all EAAS of interest
were sufficiently separated (no interference between steroids was expected to occur simultaneously
during the different incubations). All analyzed EAAS standards are depicted in the upper chromatogram
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in Figure 2. For all background incubations (absence of enzyme) no other steroids besides the substrate
were detectable. The internal standard (17α-methyltestosterone; substance K in Figure 2) was detected
in all samples.
Figure 2 shows chromatograms of samples after enzymatic incubations in solid lines. As no
substrate was detected after the incubation of Etio (etiocholanolone, substance D in Figure 2) the sample
chromatogram (solid line) was superimposed by the chromatogram of the background-incubation
(dotted line). A detailed display of chromatograms of all performed incubations and background
samples is available as supplementary data (Supplement S1). Chromatograms are displayed as total
ion current chromatograms. Hence, peaks originating from the incubation media are also present.
This is assumed to be the case for the two big peaks at 8.79 min and at 9.47 min, as both are also
present in background-samples (without enzyme). They are hence neglected in the results presentation
and discussion.
In the following paragraph, detailed outcomes of individual steroid incubations with AKR1C3
(aldo-keto reductase 1C3) will be described. After incubation of 5αAD (5α-androstanedione, substance
G in Figure 2), small amounts of substrate were detected. In addition, minor amounts of 5αDHT
(5α-dihydrotestosterone, substance H in Figure 2) and larger amounts of And (androsterone, substance
C in Figure 2) and 5αAdiol (5α-androstane-3α,17β-diol, substance E in Figure 2) were detected. All of
these compounds have a 5α-androstane structure in common and are highlighted in orange in Figure 2.
After incubation of 5βAD (5β-androstanedione, substance A in Figure 2) no or small amounts of
substrate, but peaks corresponding to 5βAdiol (5β-androstane-3α,17β-diol, substance F in Figure 2)
and Etio (substance D in Figure 2), were detected. Furthermore, very minor amounts of 5βDHT
(5β-dihydrotestosterone, substance B in Figure 2) were detectable in one of two replicates (not visible
in Figure 2). All of these compounds have a 5β-androstane structure in common and are highlighted
in green in Figure 2.
After incubation of AED (androst-4-ene-3,17-dione, substance I in Figure 2) with AKR1C3, AED
itself and its metabolite T (testosterone, substance J in Figure 2) were detected. Both compounds are
highlighted in violet in Figure 2.
After incubation of And (substance C in Figure 2) with AKR1C3, peaks corresponding to And and
5αAdiol (substance E in Figure 2) were detected. Only minor amounts of the substrate were detected
(small peak at 8.36 min with framed retention time (RT) in androsterone chromatogram in Figure 2).
And and 5αAdiol share a 5α-androstane structure and are hence highlighted in orange in Figure 2.
After incubation of Etio (substance D in Figure 2) the substrate itself was detected in only one
of the two replicates (indicated as dotted peak at 8.41 min corresponding to Etio detected in the
background sample). The metabolite 5βAdiol (substance F in Figure 2) was present in both replicates.
As Etio and 5βAdiol share a 5β-androstane structure they are highlighted in green in Figure 2.
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Figure 2. Chromatogram of EAAS standards (upper chromatogram) and steroids detected in
overview-incubations (chromatograms below) analyzed on GC-MS with substrates of incubation
indicated in upper left corner of each chromatogram and highlighted by framed retention time (RT);
colored peaks corresponding to: A: 5βAD (RT: 7.83, 8.09 min, derivatization isomers); B: 5βDHT
(RT: 7.94; 8.19 min, derivatization isomers); C: And (RT: 8.36 min); D: Etio (RT: 8.40 min); E: 5αAdiol
(RT: 8.48 min); F: 5βAdiol (RT: 8.51 min); G: 5αAD (RT: 8.85 min); H: 5αDHT (RT: 8.93 min); I: AED
(RT: 8.99 min); J: T (RT: 9.07 min); K: MeT (RT: 9.39 min; internal standard); orange peaks indicate
5α-androstanes, green peaks indicate 5β-androstanes, violet peaks correspond to T and AED, MeT is
colored in black. Peaks not indicated with RT do not correspond to any EAAS standards.
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2.2. Km Determination In Vitro
Experiments to determine the Michaelis-Menten constant (Km) of AKR1C3 catalyzed Etio
metabolism were carried out in 96-well plates to detect real-time changes in fluorescence intensities.
The Km determined with the spectro-fluorometric method was 9.7 µM (standard error of the mean;
SE = 1.4 µM; Figure 3B). As previously described, analysis of terminated incubations was additionally
carried out using a GC-QToF instrument. The determined Km with this method was 15.8 µM
(SE = 0.9 µM; Figure 3A). Michaelis-Menten curves of both measurements are depicted in Figure 3.
Figure 3. Michaelis-Menten curve of Etio with AKR1C3 generated with data from GC-QToF data (A):
Km = 15.8 µM (SE = 0.9 µM) and spectro-fluorometric measurement (B): Km = 9.7 µM (SE = 1.4 µM).
2.3. IC50 Determination In Vitro
For the measurements performed with the spectro-fluorometric method, the half maximal
inhibitory constant (IC50) could not be calculated. Several background samples (enzyme substituted
by phosphate buffered saline (PBS) 0.1 M) showed higher initial velocities than the samples which
contained enzyme. Hence, a subtraction of background-velocities from initial velocities of samples
would have resulted in negative values and hence negative enzyme activities would have been
determined. Therefore, IC50 values were determined with the data obtained by GC-QToF analysis.
The IC50 determined using the mass-spectrometric method was successful and resulted in a value
of 4.8 µM (SE = 1.0 µM). The corresponding curve is depicted in Figure 4.
Figure 4. Inhibition curve generated from GC-QToF data: IC50 = 4.8 µM (SE = 1.0 µM).
80 Manuscripts
Metabolites 2020, 10, 463 6 of 19
2.4. In Vivo Administration Trial
To illustrate all significant changes in the steroid profile markers of the male and the female
volunteers, boxplots of steroid profile markers where significant differences were found between at
least two groups are displayed in Figure 5.
Figure 5. Boxplots of steroid profile markers with significant differences between at least two groups.
(A–I): female volunteer; (J–M): male volunteer; * significant difference with p < 0.0167; ** very significant
difference with p < 0.0033; *** highly significant difference with p < 0.00033.
In the male volunteer, significant changes between at least two groups, i.e., before and during
administration, were detected for And (Figure 5J), And/T ratio (Figure 5K), And/Etio ratio (Figure 5M)
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and 5αAdiol/5βAdiol ratio (Figure 5L). The concentration of And decreased by 15% (difference in
median) during the administration of indomethacin compared to the concentration measured before
the administration and decreased by 21% (difference in mean) after the administration compared to
before the administration. The And/T ratio decreased by 11% during the administration compared to
the ratios before (difference in mean values). The And/Etio ratio increased by 5% (difference in mean)
after the administration compared to during administration and the 5αAdiol/5βAdiol ratio increased
by 9% (difference in mean) after administration compared to before administration. In the female
volunteer, significant differences were detectable for all examined steroid profile markers except for Etio
concentration and And/T ratio. Changes solely between the groups before and during administration
of indomethacin were detectable for T (Figure 5A), And (Figure 5C), 5αAdiol (Figure 5D) and 5βAdiol
(Figure 5E). Changes solely between the groups during and post administration were detectable for
E (epitestosterone, Figure 5B). Changes between the groups before/during and during/after were
detectable for T/E (Figure 5F), 5αAdiol/5βAdiol (Figure 5H) and 5αAdiol/E (Figure 5I) ratios. Changes
between the groups before/during and before/after were significant for And/Etio ratio (Figure 5G).
Furthermore, concentrations and concentration ratios of steroid profile markers, which showed
significant changes between at least two groups, were plotted over the whole sampling time. The first
sampling point was at t = 0 h. All curves are displayed in Figure 6. From this visualization it is observable
that in particular, the concentration of E and 5βAdiol and the T/E, 5αAdiol/E and 5αAdiol/5βAdiol
ratios in the female volunteer change a lot over time (Figure 6b,e,f,h and i). Additionally, for the
And/Etio ratio in the female volunteer (Figure 6g) and for the 5αAdiol/5βAdiol ratio in the male
volunteer (Figure 6l) an increase during the administration of indomethacin is clearly visible.
Indomethacin and its two evaluated metabolites were detected over the whole time of
administration. Thereby, the highest concentration of indomethacin was determined in the samples
collected after the administration of the drug (13 h). The two following samples before the next intake
(18 h and 22 h) were much lower than the detected peak-concentration. Samples collected after the
administration period (day 15 and later) contained, if at all, only trace amounts of indomethacin or its
examined metabolites (Figure 7).
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Figure 6. Time course of steroid profile markers which changed significantly over time; (a–i): female
volunteer; (j–m): male volunteer.
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Figure 7. Measured concentrations of indomethacin (blue squares) and its metabolites
O-desmethoxyindomethacin (orange circles) and N-deschlorobenzoylindomethacin (green triangles) in
urine samples collected from the male volunteer. Sampling points for one day were: 7 h, 13 h, 18 h
and 22 h.
3. Discussion
3.1. In Vitro Overview Incubation
Overview incubations were performed to examine the suitability of different endogenous steroids
as substrate for the subsequent inhibition experiments. Important requirements were:
• The substrate is an endogenous steroid, which plays a role in the steroid module of the Athlete
Biological Passport of the World Anti-Doping Agency;
• No side reaction is taking place besides the formation of the desired product;
• The initial velocity is fast enough to be monitored spectro-fluorometrically.
From those requirements it was assumed that a substrate which shows nearly complete formation of
product, with no formation of side products after 5.5 h would be an adequate candidate for the following
experiments. The requirement of no side reactions guarantees that a “one-to-one reaction” is taking
place. Therefore, NADPH (β-Nicotinamide-adenine-dinucleotide-phosphate) consumption measured
spectro-fluorometrically directly correlates with product formation measured on the GC-QToF, and the
data from spectro-fluorometric measurements and chromatographic confirmation are comparable.
The nearly complete formation of the product after a (rather long) incubation period of 5.5 h indicates a
higher reaction velocity which would result in a higher sensitivity of the spectro-fluorometric analysis.
For all enzymatic incubations, the formation of product(s) was observed. Hence, a negative effect
of methanol or acetonitrile (used as solvents for steroid substrates) on the outcome of the qualitative
experiments was not expected.
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Five endogenous steroids were chosen for preliminary experiments. 5α- and 5β-androstanedione
formed three products each, which was not expected, since all other examined EAAS only showed the
formation of one product. Following the pattern of all other observed products, we assumed that also
5α- and 5β-androstanedione would form their 17-hydroxy-metabolite, 5α- or 5β-dihydrotestosterone,
respectively. However, we only detected small amounts, of the latter and of the substrates, if any. Instead,
we observed the formation of And or Etio and 5αAdiol or 5βAdiol, respectively. Those findings are in
accordance with the literature, where AKR1C3 is described to act as 3α-hydroxysteroid dehydrogenase
(3αHSD) as well as 17βHSD [16]. Further investigations would be interesting to evaluate the complex
kinetics and the metabolite formation sequence to gain further insights into enzyme characteristics.
In the analyzed samples of AED, And and Etio, only one product was detected. Whereas AED
and And formed their corresponding product T and 5αAdiol in relatively small amounts in both
replicates, Etio was converted nearly completely into its product 5βAdiol in one of two replicates
(Figure 2). Due to the complete metabolization and the absence of any side reactions, Etio was chosen
as the substrate for the subsequent in vitro kinetic experiments.
3.2. Kinetic Measurements In Vitro
To prevent the potential interfering effects of acetonitrile or methanol (used as solvent of the
steroid substrate for qualitative incubations) with the enzyme, Etio was dissolved in DMSO (dimethyl
sulfoxide) for all the kinetic measurements. Constant volumes of DMSO and ethanol were added
to all incubations (with and without indomethacin and to samples without enzyme) to generate
comparable results.
To find the optimal substrate concentration for the subsequent inhibition experiments,
the Km value of the AKR1C3-catalyzed reduction in Etio is needed. These values were determined
experimentally since, to our knowledge, no kinetic data on the desired reaction are available in the
literature. The Km values from the spectro-fluorometric and mass spectrometric measurements
(Km(fluoro) = 9.7 µM, standard error of the mean; SE = 1.4 µM and Km(QToF-MS) = 15.8 µM
(SE = 0.9 µM) show that the method used to analyze the kinetic experiments has an impact on
the determined Km value. Despite the difference in the Km values determined with the two methods,
the examined reaction has an efficiency comparable to other steroid-reductions catalyzed by AKR1C3
reported in the literature [12,16]. The reactions of steroid substrates are relatively inefficient compared
to other substrates converted by AKR1C3, e.g., 9,10-phenanthrenequinone (Km = 1.5 ± 0.7 µM) [12,17].
This may explain why the spectro-fluorometric method showed good results for the Km determination,
but not for inhibition experiments. Initial velocities in the inhibition experiments were generally
lower than those determined in the Km experiments, resulting in lower sensitivities. The presence of
indomethacin may be another explanation for the unsuitability of the spectro-fluorometric method for
the inhibition experiment. In background reactions, we observed that large amounts of indomethacin
led to quenching of the fluorescence intensity generated by NADPH. Generally, subtracting the
background signal from the sample-signal should compensate for this difference. Nevertheless,
we observed that in particular, background samples with high amounts of indomethacin resulted
in higher initial velocities than the corresponding samples with the enzyme. As the evaluation of
those data would result in negative enzyme activities and in activities far above 100%, the applied
spectro-fluorometric method is not suitable to determine the IC50 value of the inhibition of AKR1C3
catalyzed reduction in Etio. Due to those difficulties in the spectro-fluorometric method, the IC50
was determined using mass spectrometry. The determined value of 4.8 µM (SE = 1.0 µM) was
transformed into an inhibition constant (KI) using the “IC50-to-KI-converter” [18]. Byrns et al. reported
a competitive inhibition type of indomethacin on the reduction in androstenedione by AKR1C3 [12].
Assuming that the inhibition of the AKR1C3 catalyzed reduction in Etio follows the same pattern,
the calculated KI would be 2.2 µM. This result is in accordance with findings from the literature, where
different substrates were used [12,19,20]. The determined KI lies on the upper range of the therapeutic
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blood-plasma/serum concentration of the drug (0.84–2.8 µM) [21], resulting in the hypothesis for the
in vivo experiments that therapeutic doses of indomethacin may lead to relevant inhibition of AKR1C3.
3.3. In Vivo Administration Trial
As AKR1C3 plays a crucial role in the metabolism of EAAS, used as markers in doping control
analysis, we assumed that the intake of therapeutic doses of indomethacin may lead to changes in the
steroidal profile. Since the aim of this study was getting a first idea on the detectability of changes
in the steroid profile after the intake of therapeutic doses of indomethacin over 14 days, only one
male and one female volunteer were included in the study. Despite this limited number of volunteers,
we are convinced that the presented results are relevant for the anti-doping community and other
fields where steroid quantification is of importance. As the knowledge of so-called confounding factors
is of paramount importance for the interpretation of steroid profiles [10], this study will be of value
for improved interpretation of steroid profiles. To enhance the exploration of factors influencing the
steroid profile, we want to share our findings to raise awareness and induce further in-depth research.
Statistical analysis of in vivo data showed significant changes between the groups (before, during
and after indomethacin administration) for several EAAS in both volunteers (Figures 5 and 6). While
in the male volunteer only four steroid profile markers changed significantly (A, And/T, And/Etio
and 5αAdiol/5βAdiol), nine of the 11 markers changed in the female volunteer. This is in accordance
with our previous study on the influence of ibuprofen intake on the steroid profile, where only a few
steroid profile markers were affected in the male volunteer, while the majority of markers changed
significantly in the female volunteer [22].
Due to the experimental setting, both individual and sexual differences may be explanations for
this effect. However, sexual differences seem to be reasonable as an explanation. As females have lower
concentrations of EAAS than males, their concentrations and concentration ratios monitored in the
steroid profile of the Athlete Biological Passport are much more affected by exogenous and endogenous
parameters (e.g., menstrual cycle, intake of contraceptives or emergency contraceptives, ethanol) [23,24].
Mullen et al. showed that the epitestosterone concentration changes significantly during the menstrual
cycle, and hence the T/E and 5αAdiol/E ratios are significantly affected. Similar observations are true
for the female volunteer in this study who did not take any oral contraceptives for at least six months
before and during the study. In particular, the concentration of E, the T/E and the 5αAdiol/E ratios
changed a lot over the whole collection time (Figure 6). The influence of physiological changes on
these parameters may need further investigation. In a publication by Mareck-Engelke et al. [25] also
considering the potential circadian rhythm and the menstrual cycle in females, the And/Etio ratio is
reported to be the most stable, but also the 5αAdiol/5βAdiol ratios showed a coefficient of variation
(CV) <30%. However, both ratios (A/Etio and 5αAdiol/5βAdiol) changed significantly in the female
volunteer during indomethacin application. In addition, the concentrations of And and 5αAdiol
increased significantly, while the concentration of 5βAdiol decreased significantly during the intake.
In the male volunteer, the picture is not as complex as in the female volunteer. The significant
decrease in And/T ratio may be explained by the decrease in And during the intake of indomethacin.
The 5αAdiol/5βAdiol ratio increased significantly during the intake of indomethacin, which is in
accordance with the observations from the female volunteer.
For both volunteers, several steroid profile markers changed significantly under the influence
of indomethacin but no criteria for a suspicious steroid profile during an anti-doping test were
met for a sequence of successive samples. Nonetheless, selected concentrations and concentration
ratios were significantly influenced by the intake of the drug. Additionally, the concentrations of
indomethacin and its metabolites O-desmethylindomethacin and N-deschlorobenzoylindometacin were
determined in the urine samples collected from the male volunteer to obtain some first information
on the long-time influence of indomethacin on the steroid profile. It was found that the highest
concentrations of indomethacin are detectable in the sample which was collected after the drug intake.
The samples collected after this and before the next indomethacin administration contained much
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lower concentrations (Figure 7). This is in accordance with the half-life of 3–11 h [21]. Based on the
half-life, and since indomethacin and its monitored metabolites are only detectable in urine samples
collected close to the intake of the drug, one would assume that no differences in steroid profile
markers are observable between samples collected before and after indomethacin intake. Nevertheless,
there are a few significant changes in the steroid profile detectable between samples collected before
and after the administration of indomethacin (Figure 5G,J,L). Other profile markers are affected
during the intake of the drug but show no significant difference between the groups during and after
indomethacin intake (Figure 5A,C–E,K). An explanation of these effects may be a prolonged influence
of indomethacin on AKR1C3 and thus also the steroidal profile. To further investigate the significance
for doping-control analysis and to reassess our hypothesis a study with a higher number of volunteers
is already in preparation.
In addition to the impact on results interpretation in anti-doping analysis, the presented results are
also relevant in evaluating potential endocrine disrupting substances (EDS). Like several other NSAIDs,
indomethacin has anti-inflammatory, anti-pyretic and analgesic effects. It inhibits the cyclooxygenase
and hence the formation of prostaglandins (PGs) which are responsible for the manifestation of pain,
inflammation and fever. The literature reports that many putative EDSs inhibit the PG synthesis [26].
Additionally, the literature also discusses the role of PG synthesis inhibition by indomethacin in the
mechanism of endocrine disruption [27,28]. However, it is accepted that probably not only the inhibition
of PG synthesis is involved. Previous studies showed that indomethacin interferes with the testosterone
production in various models [26,27,29–32]. Barkay et al. reported that plasma-testosterone levels in
oligospermic men decreased significantly after an intake of indomethacin (75 mg over 90 days) [30].
In comparison, Knuth et al. reported an investigation with an administration of a lower dose and
shorter duration (25 mg indomethacin per day over 14 days, i.e., similar to our administration).
No significant change was detectable in the serum testosterone concentration in young, healthy male
volunteers. This is in accordance with our presented findings, where no significant changes in the
urinary testosterone concentration were detectable in the male volunteer. In the female volunteer,
where steroid profile markers were showed to be more easily affected, significant changes in the
urinary testosterone concentrations were detectable during the intake of indomethacin compared
to pre-administration. Future investigations could hence investigate whether higher daily doses or
prolonged administrations of indomethacin would also affect testosterone levels in the male volunteer.
Additionally, studies on the impact of indomethacin on AKRs were published [12,19], and in vitro
experiments presented in our study showed the effect of indomethacin on the AKR1C3 catalyzed
reduction in Etio. All investigations commonly show that indomethacin inhibits AKR1C3 in vitro.
Among other catalyzed reactions, this enzyme plays a key role in the metabolism of androgens,
estrogens and progestagens [16]. As AKR1C3 is implicated in some hormone dependent malignancies
and endocrine disorders, drugs selectively inhibiting AKR1C3 are investigated to be used as cancer
treatment or drugs treating endocrine disorders for patients where this enzyme is overexpressed [33].
Our work demonstrates that the inhibition of AKR1C3 by indomethacin alters selected markers of
the urinary steroid profile in healthy volunteers. In the context of AKR1C3 involvement in androgen,
estrogen and progestin metabolism, an effect on estrogens may also be hypothesized. Based on our
study and on findings from the literature, the risk potential of indomethacin and its role as endocrine
disruptor should be reinvestigated.
4. Materials and Methods
4.1. Materials
Androst-4-ene-3,17-dione (AED), 17β-hydroxyandrost-4-en-3-one (testosterone; T),
17α-hydroxyandrost-4-en-3-one (epitestosterone; E), 3α-hydroxy-5α-androstan-17-one
(androsterone; And), 5α-androstane-3,17-dione (5α-androstanedione; 5αAD), 17β-hydroxy-5α-
androstan-3-one (5α-dihydrotestosterone; 5αDHT), 5α-androstane-3α,17β-diol (5αAdiol), 3α-hydroxy-
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5β-androstan-17-one (etiocholanolone; Etio), 5β-androstane-3,17-dione (5β-androstanedione; 5βAD),
17βhydroxy-5β-androstan-3-one (5β-dihydrotestosterone; 5βDHT), 5β-androstane-3α,17β-diol
(5βAdiol) and 17α-methyltestosterone (MeT; used as internal standard) were from Steraloids (Newport,
RI, USA), Sigma-Aldrich (Milano, Italy) or TCI (Eschborn, Germany). Deuterated standards T-d3,
E-d3, And-glucuronide-d4, Etio-d5, 5αAdiol-d3, 5βAdiol-d5 were obtained from the National
Measurement Institute (NMI, Lindfield, NSW, Australia). Indomethacin, O-desmethylindomethacin
and N-deschlorobenzoylindomethacin used as reference compounds for the excretion study were
all purchased from TRC (Toronto Research Chemicals, North York, ON, Canada). Probenecid as
internal standard was from Sigma Aldrich (Milan, Italy). Indomethacin, used as inhibitor for in vitro
experiments, was of European Pharmacopoeia (Ph. Eur.) quality and purchased from Sigma-Aldrich
(Steinheim, Germany). For the in vitro assay, solutions of different concentrations of the substrate
Etio (20 µM, 100 µM, 200 µM, 400 µM, 1 mM, 2 mM) and the inhibitor indomethacin (6 µM, 20 µM,
60 µM, 200 µM, 600 µM, 2 mM) were prepared from stock solution by dilution of the solid substance in
DMSO in the case of Etio and in ethanol in the case of indomethacin. Solvents (ethanol, acetonitrile,
DMSO, tert-butyl methyl ether (TBME), methanol or ethyl acetate) and reagents (sodium phosphate
and sodium hydrogen phosphate, potassium carbonate and sodium hydrogen carbonate, acetic acid
and sodium acetate) were of analytical, high performance liquid chromatography (HPLC) or of
high performance liquid chromatography-mass spectrometry (HPLC-MS) reagent grade and were
purchased from Merck (Darmstadt, Germany), Carl Roth (Karlsruhe, Germany), Honeywell Fluka
(Milan, Italy) or Sigma Aldrich (Milan, Italy). NADPH regenerating system solution A and solution B
were used for the overview incubations and were purchased from Corning Gentest (Woburn, MA,
USA). The cofactor for the enzymatic incubations to determine the kinetic values Km and IC50 was
NADPH-tetra-sodium salt (NADPH-Na4) and was purchased from Carl Roth (Karlsruhe, Germany).
The human recombinant enzyme AKR1C3 (expressed in Escherichia coli (E. coli, catalogue number:
NBC1-21051) originated from Novus Biologicals Europe (Abingdon, United Kingdom). Phosphate
buffered saline (PBS, 0.5 M, pH 7.4) from Corning Gentest (Woburn MA, USA) was diluted and
used for all in vitro experiments. The preparation of β-glucuronidase from E. coli was from Roche
Diagnostic (Mannheim, Germany). N-methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA) was
supplied by Chemische Fabrik Karl Bucher GmbH (Waldstetten, Germany), ammonium iodide
(NH4I), mercaptoethanol and ethanthiol were from Sigma Aldrich (Milano, Italy or Taufkirchen,
Germany). Water was obtained from a “MilliQ” (Millipore S.p.A., Milano, Italy) or from “SG LaboStar”
(Guenzburg, Germany) water purification system.
4.2. In Vitro Qualitative Incubation
Incubations were performed in duplicate in parallel to a background sample where the volume of
enzyme was substituted by PBS 0.1 M. NADPH regenerating system (consisting of 1.3 mM NADP+,
3.3 mM glucose-6-phosphate and 3.3 mM magnesium chloride and 0.4 U/mL glucose-6-phosphate
dehydrogenase in final assay), AKR1C3 (0.64 µM in final assay) and PBS 0.1 M were added to a 1.5 mL
reaction tube, centrifuged briefly and prewarmed at 37 ◦C for 5 min. AED, And, 5αAD, 5βAD or
Etio (dissolved in methanol or acetonitrile; concentration in stock solution 1 mg/mL) were added as
substrates (final concentration in assay: steroid ~50 µM, solvent 1.5% (v/v)). After brief centrifugation,
incubation was carried out for 5.5 h at 37 ◦C. Incubation was terminated by the addition of 200 µL cold
acetonitrile and samples were extracted immediately or stored at −20 ◦C until extraction.
4.3. In Vitro Kinetic Assay
All incubations were performed in triplicate. The incubations were carried out in 96-well plates
(black, flat black bottom, Sarstedt, Nümbrecht, Germany) and analyzed spectro-fluorometrically in
real-time. After incubation, the entire assay-volume was transferred to a 0.5 mL reaction tube and
200 µL of cold acetonitrile were added to denature the enzyme and thereby end the reaction. Samples
were stored at −20 ◦C until confirmative GC-QToF analysis was performed. For each experiment
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NADPH solution (in PBS 0.1 M) was prepared freshly. Ethanol or indomethacin dissolved in ethanol,
NADPH (12 µM in final assay) in PBS 0.1 M, AKR 1C3 (1.03 µM in final assay) and PBS 0.1 M were added
to the appropriate location on the well-plate. The mixture was prewarmed for 3 min at 37 ◦C under
agitation. After the addition of Etio, the plate was centrifuged briefly, and incubation was performed
for 1000 s in the plate reader. Concentrations of Etio for Michaelis-Menten-constant (Km)-determination
were 1 µM, 5 µM, 10 µM, 20 µM, 50 µM or 100 µM in the final assay. In experiments to evaluate
the half maximal inhibitory concentration (IC50), Etio was used in a concentration slightly below the
determined Km (7 µM in final assay) throughout. Indomethacin (dissolved in ethanol) was added,
resulting in concentrations of 0.1 µM, 0.3 µM, 1 µM, 3 µM, 10 µM, 30 µM or 100 µM in final assay.
4.4. Administration Study
Two healthy volunteers, one male and one female (additional information on volunteers in Table 1),
were treated with indomethacin (Indoxen 25 mg; Recordati S.p.A.; Milan, Italy) for 14 days. Urine
samples were collected 4 times per day for five days prior to the treatment and the whole treatment
phase (sampling points: 07:00 h; 13:00 h, 18:00 h and 22:00 h) and one time per day after the treatment
phase (sampling point 13:00 h over 11 days for male volunteer and 8 days for female volunteer). Urine
samples were anonymized and stored in sterile plastic tubes at −20 ◦C until analysis. The study was
approved by the “Comitato Etico Lazio 1” with the reference number: 1553/CE Lazio 1. All volunteers
gave informed consent.
Table 1. Additional information on male and female volunteer included in this study.
Male Volunteer Female Volunteer
Age 29 30
Weight 63 kg 60 kg
Hight 172 cm 178 cm
BMI 21.3 kg/m2 18.9 kg/m2
Dietary habits Normal diet (no restriction) Normal diet (no restriction)
Training Three times/week (swim and run) No
Oral contraceptive Ø No
4.5. Sample Preparation before Chromatographic Analysis
In case of in vitro samples (overview incubations and kinetic experiments), MeT (in methanol;
10 µL of 1 g/L-solution for overview study or 10 µL of 0.1 g/L-solution for kinetic study) was added.
Samples were centrifuged (at 9660× g) to sediment the denatured enzyme. Supernatant was transferred
to fresh glass-tubes and 1 mL PBS 0.1 M and 5 mL TBME (in case of kinetic experiments) or 2 mL ethyl
acetate (in case of the overview incubations) were added.
For all urine samples, specific gravity was determined, to normalize steroid and NSAID
concentrations according to the WADA technical document TD2018EAAS, using a digital refractometer
RM40 (Mettler Toledo, Novate Milanese, Italy) [3]. Steroids (free and glucuronide fraction) were
extracted using an already established protocol for steroid profiling of endogenous steroids, which
is used routinely in the Italian anti-doping laboratory, Rome [34–36]. In brief, 2 mL of urine, 30 µL
of β-glucuronidase, 750 µL of 0.8 M PBS and 50 µL of internal standard (T-d3: 100 ng/mL, E-d3:
25 ng/mL, And-d4 glucuronide: 200 ng/mL, Etio-d5: 200 ng/mL, 5αAdiol-d3: 50 ng/mL, 5βAdiol-d5:
50 ng/mL, MeT: 250 ng/mL) were mixed and heated for 1 h at 55 ◦C. After hydrolysis, 500 µL of
carbonate/bicarbonate buffer (20% (w/v), pH 9) and 5 mL TBME were added.
For the extraction of indomethacin and its metabolites, 1 mL of urine, 50 µL probenecid (1 µg/mL)
as internal standard, 30 µL of β-glucuronidase and 500 µL PBS 0.8 M were added and hydrolysis was
achieved after 1 h of incubation at 55 ◦C. Before extraction, 500 µL sodium acetate buffer (pH 5) and
5 mL TBME were added.
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For in vitro and urine samples, liquid-liquid extraction was performed during agitation on
an automated shaker. Samples were centrifuged briefly (relative centrifugal force was 1008× g) to
separate the phases. The organic layer was transferred to new glass tubes after 5 min freezing in
an ethanol bath (−25 ◦C) or overnight at −20 ◦C in the freezer. The solvent was evaporated under
nitrogen at elevated temperatures and derivatization was performed at 75 ◦C for 30 min with 50 µL
MSTFA/mercaptoethanol/NH4I (1000:6:4 v/v/w; in case of in vitro kinetic samples and urine samples)
or MSTFA/ethanthiol/NH4I (1000:3:2 v/v/w; for overview incubations).
4.6. Fluorometric Analysis
Spectro-fluorometric measurements to determine the kinetic values of the enzymatic reaction
were carried out on a Safire II microplate reader (Tecan, Männedorf, Switzerland) in top-read mode.
Excitation wavelength was 340 nm, emission wavelength was 450 nm with both bandwidths set to
5 nm. For all experiments, gain was 120 and Z-position was 10,300 µm. Time between move and flash
was 10 ms, integration time 40 µs and 0 µs lag time. In the beginning of all experiments performed on
the plate reader, a calibration with 8 different concentrations of NADPH in PBS 0.1 M was performed.
For each concentration, 200 µL of NADPH solution were pipetted to 10 individual wells and each well
was measured with the same method used for kinetic experiments. The resulting calibration curve
was tested for linearity (Mandel-test, p = 99%), homogeneity of variances following DIN 38 402 A51
(p = 99%, including Grubbs outlier-test) and limit of quantification (LOQ) was determined following
DIN 32 645 (p = 95%, confidence level: 95%).
4.7. GC-MS Analysis
Samples originating from overview incubations were analyzed on an Agilent 7890A GC-System
coupled to an Agilent 5975C MSD (Agilent Technologies, Santa Clara, CA, USA). Injection volume was
2 µL with split injection in a ratio of 1:10. Injection temperature was set to 300 ◦C. Chromatographic
separation was achieved on an Agilent HP1 column (length: 17 m; diameter: 0.2 mm; film-thickness:
0.11 µm) with helium as carrier gas and a flow-rate of 1 mL/min. Oven program started at 193 ◦C
with 3 ◦C/min heating rate to 215 ◦C followed by a ramp with 40 ◦C/min to 310 ◦C and hold for 1 min.
Ionization was electron ionization (EI) and analysis was performed in scan mode with acquisition from
m/z 40 to m/z 750.
4.8. GC-QToF Analysis
Instrumental analysis of kinetic in vitro samples was performed on an Agilent GC-QToF 7890B/7200
(Agilent Technologies, Milano, Italy), equipped with an Agilent HP1 column (length: 17 m; diameter:
0.2 mm; film-thickness: 0.11 µm) with helium as carrier gas and a flow of 0.8 mL/min. Injection was
performed in split mode with a 1:10 ratio at 280 ◦C. The oven program had the following heating
rates: 188 ◦C hold for 2.5 min, 3 ◦C/min to 211 ◦C and hold for 2 min, 10 ◦C/min to 238 ◦C, 40 ◦C/min
to 320 ◦C and hold for 3.2 min. The coupled QToF was operated in full scan with an EI source and
ionization energy of 70 eV. Ions were detected from m/z 50 to m/z 750.
Calibration was performed with 9 different concentrations of 5βAdiol with fixed concentrations
of MeT. Each calibration level was measured twice. Calibration was tested for linearity applying the
Mandel Test, tested for outliers (no residuals >3 standard deviations) and weighted with a factor 1/x.
A signal to noise ratio of 10 to 1 was regarded as LOQ. Samples with signals below the LOQ were
regarded as not containing any analyte.
4.9. GC-MS/MS Analysis
For urinary steroid profile analyses, a previously described method was used [34–36]. It is validated
and currently used in routine analysis for the detection and quantification of pseudo-endogenous
steroids in the Italian anti-doping laboratory in Rome and accredited under ISO17025. In brief, analyses
were performed on an Agilent GC-MS/MS 7890 A/7000 (Agilent Technologies, Milano, Italy) equipped
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with an Agilent HP1 column (length: 17 m; diameter: 0.2 mm; film-thickness: 0.11 µm). The carrier gas
was helium with a flow rate of 1 mL/min, and the injection and transfer line temperature were set to
280 ◦C and injection was performed in split mode with a ratio of 1:20. The oven program was as follows:
180 ◦C hold for 4.5 min, 3 ◦C/min to 230 ◦C, 20 ◦C/min to 290 ◦C and 30 ◦C/min to 320 ◦C. Ionization
was achieved by EI and ionization energy was 70 eV. Analyses were performed in multiple-reaction
monitoring mode (MRM mode) with transitions used in the reference method. Quantitation of the
urinary steroids was based on the peak area ratio of the analyte to the corresponding internal standard.
Calibration and quality control samples were prepared in synthetic urine according to previously
published methods [37].
For quantification of indomethacin and its metabolites, a similar method was used. Aberrantly,
the oven program was 85 ◦C initial temperature hold for 1 min, 15 ◦C/min to 320 ◦C. Transitions for
analyzed compounds are listed in Table 2. Selectivity, linearity, repeatability, recovery and limit of
detection (LOD) were tested for the evaluation of method suitability (data not shown).
Table 2. Transitions for GC-MS/MS analysis of indomethacin and its metabolites
O-desmethylindomethacin and N-deschlorobenzoylindomethacin and the internal standard probenecid.
Analyte Precursor Ion [m/z] Product Ion [m/z] Collision Energy [eV]
Indomethacin (mono-TMS) 429 139; 246; 312 30; 30; 30
O-desmethylindomethacin (bis-TMS) 487; 304 139; 216; 232 30; 30; 30
N-deschlorobenzoylindomethacin (bis-TMS) 363; 348; 246 246; 320; 174 30; 10; 30
Probenecid (mono-TMS) 178; 342 104; 268 20; 20
4.10. Data Analysis of Kinetic Values
To determine the Michalis-Menten constant, initial velocities of the enzymatic reactions were
plotted against the concentration of Etio. Nonlinear regression was applied to the data using
OriginPro, Version 2019 (OriginLab Corporation, Northhampton, MA, USA). For spectro-fluorometric
measurements, the loss in fluorescence intensity over time curves were transformed in loss of
NADPH-concentration over time using a calibration curve. By applying linear regression to those
concentration-time curves, the initial velocity was determined. Initial velocities for the individual
samples were corrected with the background velocities. For mass spectrometric data the determined
concentration of formed product (5βAdiol) over time of incubation was regarded as initial velocity.
As no product was present in background incubations, no correction of this value was performed.
GC-QToF data were analyzed using Agilent MassHunter Workstation Quantitative Analysis for TOF
(Version 10.1; Agilent Technologies, Santa Clara, CA, USA).
To determine the IC50 values of the inhibition experiments, activity of the enzyme was plotted
against logarithmic concentrations of the inhibitor indomethacin in the assay. The activity of the
enzyme was calculated as a quotient of the initial velocities of the sample and the initial velocities
of the positive control (no inhibitor added). Nonlinear regression was performed using OriginPro,
Version 2019.
4.11. Data Analysis of Steroid Profiling and Indomethacin Detection in Urine Samples
Measured concentrations of EAAS, indomethacin and its metabolites were normalized for the
specific gravity of the sample according to the WADA technical document TD2018EAAS [3]. Samples
with a specific gravity at or below 1.001 were excluded from the analysis. For samples in which selected
analytes had concentrations below the limit of quantification (LOQ), the analyte in question and its
related ratios were excluded from analysis.
For the steroid-profiling samples of each volunteer were divided into three groups: before
treatment with indomethacin (n = 20) during the administration (n = 56 for male volunteer; n = 55 for
female volunteer due to exclusion of one sample where specific gravity was 1.001 and n = 54 for female
volunteer for E, T/E, 5αAdiol/E because concentration of E was below LOQ in this sample) and after
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indomethacin intake (n = 11 for male volunteer and n = 8 for female volunteer). The data were regarded
as independent from each other. All measured concentrations belonging to one group (per volunteer,
per substance, and phase during treatment) were tested for normal distribution (Shapiro Wilk test,
α = 0.05). In case of normal distribution the homogeneity of variances between the groups was also
tested (F-Test, α = 0.05). If the hypothesis of normal distribution was not rejected for both groups
examined, a two-sided parametric significance test for independent samples was applied. In case of
homogeneity of variances between groups, a two-sided t-test for independent groups was applied.
In case of rejection of homogeneity of variances between groups, Welch-Test was used. When for at least
one of the two examined groups the null-hypothesis of normal distribution had to be rejected, the less
powerful non-parametric Mann-Whitney U-Test was applied. For all significance tests (parametric and
non-parametric) the significance level was α = 0.0167 to deal with multiplicity problems of statistical
tests [38].
Normalized concentrations of indomethacin and its metabolites were plotted against the time
after first dose of indomethacin was administered.
5. Conclusions
The presented work shows the complexity of steroid metabolism in vitro and in vivo.
It furthermore reveals the advantages and drawbacks of different analysis methods for in vitro
enzymatic assays. A combination of in vitro and in vivo experiments was performed showing the
interference of the non-steroidal anti-inflammatory drug indomethacin with androgen metabolism and
the effect of indomethacin on the urinary steroid profile. The study provides results which can help to
interpret steroid profiles in anti-doping analysis. The presented results may also be relevant for other
fields of forensic or clinical toxicology and for the investigation of endocrine disrupting substances
(EDS). Future investigations on long-term effects or the influence of higher doses of indomethacin may
extend our findings.
Supplementary Materials: The following are available online at http://www.mdpi.com/2218-1989/10/11/463/s1.
Supplement S1: Chromatograms of in vitro qualitative incubation.
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The following document displays chromatograms obtained after incubation of the 
endogenous anabolic androgenic steroids (EAAS) 5α-androstanedione, 5β-androstanedione, 
androstenedione, androsterone and etiocholanolone with isolated recombinant human aldo-
keto reductase (AKR) 1C3. 
Similarely to the main document all 5α-androstanes are highlighted in organge, all 5β-
androstanes are highlighted in green, testosterone and androstenedione are highlighted in 
violett and the internal standard methyltestosterone (MeT) is highlighted in grey. 
To simplify the graphics, substrates are highlighted by framed retention times (RT) and all 
detected EAAS are labeled with abbreviations: And: androsterone, 5αAdiol: 5α-
androstanediol, 5αAD: 5α-androstanedione, 5αDHT: 5α-dihydrotestosterone, Etio: 
etiocholanolone, 5βAdiol: 5β-androstanediol, 5βAD: 5β-androstanedione, 5βDHT: 5β-
dihydrotestosterone, T: testosterone, AED: androstenedione. 
Comment: As the peak corresponding to 5βDHT in sample 1 (incubation of 5βAD with 
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5 DISCUSSION AND OUTLOOK 
e results presented in this work are of interest in scientific areas performing steroid analysis 
or in fields where the knowledge of steroid metabolism and its influenceability is of important 
relevance. is includes but is not limited to forensic toxicology, clinical and endocrinological 
analysis and trace analysis (e.g. in wastewater or dietary supplements). e central topic of this 
work, however, is anti-doping research, which is intended to exemplify the relevance of the results 
presented. Some major challenges in the detection of AAS misuse in sport will be illustrated based 
on a publication by Geyer et al. [80]. e impact of the presented work on the mentioned challenges 
will be discussed in a first step. Subsequently, broader applications will be assessed to address the 
two major aims of this work. e first aim is to illustrate the relevance of studies on the steroid 
metabolism and its influenceability for a broader community. e second aim is the provision of 
helpful insights to enhance currently used methods to detect the misuse of anabolic androgenic 
steroids and hence to improve the detection of prohibited performance enhancing substances in 
sports doping. e fundamental knowledge on the general testing procedure for the detection of 
AAS administration used in anti-doping analysis is favourable to identify challenges in the testing 
process. Chapter 2.3 gives a deeper insight in the whole process. However, to facilitate the 
understanding of this discussion the basic steps will be repeated. 
e basis for the detection of AAS misused as doping substances is steroid profiling. erefore, 
concentrations and concentration ratios of EAAS are determined in urine samples collected from 
the athletes. Results are reported to the steroidal module of the athlete biological passport. Intake 
of pseudo endogenous AAS and long-term administration of synthetic AAS leads to steroid profile 
alterations which allows the detection of the prohibited intake of these substances. Hence, by 
evaluating alterations of specific endogenous steroids used as markers, a broad number of known, 
as well as unknown analytes are detectable in an indirect manner [80]. In addition to the prohibited 
intake of AAS, altered steroid profiles may be caused by other endogenous or exogenous factors, 
as already mentioned in Chapter 2.3.4. erefore, anti-doping laboratories monitor the presence of 
known confounding factors, meaning conditions influencing markers monitored in the steroid 
profile, to interpret testing results more accurately. Also non-prohibited drugs have been reported 
to leading to steroid profile alterations mainly by interfering with the steroid metabolism [91, 94, 
104, 107]. If changes in the steroid profile are interpreted in a wrong manner, they may adulterate 
testing results in doping control and hence cause false decisions. e awareness of substances 
causing steroid profile alterations helps to prevent incorrect decisions and save cost- and time-
consuming confirmative analysis in doping control by tracing back atypical profiles to the presence 
of specific confounding factors (e.g. intake of drugs). 
e use of the ABP and hence the calculation of individual limits for each athlete and each 
marker of the steroidal profile made it possible to detach analytical results from individual 
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endogenous factors influencing the steroid profile (e.g. sex, age and genetic factors). Nonetheless, 
research on confounding factors that do not have an endogenous origin (e.g. medication or stress) 
is crucial for interpretation of results, as they are not adequately recorded by the ABP and therefore 
possibly cause divergent analysis results. One example may be a potential scenario from anti-
doping analysis: the occasional application of drugs influencing the steroid metabolism. e 
infrequent intake of such drugs may cause testing results outside of the individual limits calculated 
by the adaptive model of the ABP and hence cause a suspicious or atypical testing result. Another 
scenario from anti-doping analysis may be the repeated or regular intake of non-prohibited drugs 
interfering with the steroid profile. is potentially causes steroid profile alterations which are still 
in the individual limits calculated by the adaptive model but may cause higher variations and hence 
lead to broader individual limits as it would be the case without the intake of these drugs. A 
potential intake of pseudo endogenous AAS, especially when administered in micro doses only, 
may hence be missed. Consequently, investigations on factors interfering with the endogenous 
steroid profile are of paramount relevance. 
As already mentioned in Chapter 2.1.2, the influence on metabolic reactions of endogenous 
compounds is one key characteristic of endocrine disrupting substances. Investigations on 
substances influencing the metabolism of EAAS may hence contribute to a renewed risk-
assessment of drugs. Based on the same mechanism, these substances interfering with certain 
metabolic steps can be used in the development of novel drugs. ereby the endocrine disrupting 
effect of these substances is used to suppress the production of specific endogenous steroids. With 
5α-reductase inhibitors and aromatase inhibitors two classes of substances currently used as 
therapeutic drugs are mentioned exemplarily. Furthermore, the knowledge of confounding factors 
leading to divergent analytical results is of relevance in all fields where steroid detection and 
quantification is performed. 
Manuscript III and Manuscript IV are investigating effects of ibuprofen and indomethacin 
on selected enzymatic reactions involved in the steroid metabolism in vitro and on selected 
endogenous steroid concentrations and ratios, used as markers in the steroidal profile of the ABP, 
in vivo. NSAIDs are very frequently used not only in athletes [15, 27, 109-111]. Hence, the presented 
results may be of important relevance for the evaluation of confounding factors in anti-doping 
analysis as well as in other fields where steroid metabolism and the detection of intermediates in 
the steroid metabolism plays a role. To further illustrate the relevance for anti-doping analysis one 
example for the previously described scenario of chronical intake of potentially confounding 
substances may be an athlete regularly administering NSAIDs. e consequences for the health 
and the spirit of sport are discussed in the recently broadcasted German documentary 
“Geheimsache Doping - Hau rein die Pille” [108]. e results from this thesis present that, besides 
the risk for health and the violation of the spirit of sport discussed in the documentary, also steroid 
profile alterations may result from the intake of ibuprofen and indomethacin. Especially the 
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prolonged administration of higher doses may lead to androgen disbalances. Women in particular 
may be affected, as their androgen levels are naturally much lower than those of men. As 
mentioned earlier, NSAIDs are currently neither included in the WADA Prohibited List nor in the 
monitoring list and not even considered as confounding factors, yet. e results of Manuscript III 
and Manuscript IV hence provide a valuable basis for further investigations on the potential of 
ibuprofen and indomethacin to enhance performance in sport. 
In a broader context the presented work demonstrates that the inhibition of enzymes involved 
in steroid metabolism is of relevance in the mechanism of steroid profile alteration, which may 
cause endocrine disruption. Endocrine disrupting effects had been described previously for NSAIDs 
(Chapter 2.1.2). e presented findings may hence be of relevance in reinvestigating the risk 
potential of NSAID intake. In this context the evaluation of potential interfering effects of NSAIDs 
on the metabolism of endogenous corticoids or on the pharmacokinetic of simultaneously taken 
glucocorticoid drugs would be interesting. As the application of NSAIDs and glucocorticoids is a 
very common therapeutical combination of drugs, the evaluation of potentially interfering effects 
may be of great value. 
As mentioned earlier, the ability of substances to interact with the endogenous metabolism can 
be used to develop new drugs. Several publications show promising in vitro results on the use of 
NSAIDs and related compounds as possible new drug candidates in the treatment of cancer [112, 
114, 115]. Findings from this thesis may help to get one step closer to this goal. 
Finally, the two manuscripts illustrate, that results from in vitro experiments help to beer plan 
and perform in vivo application trials (also discussed in Chapter 2.2). In vitro results can be used to 
estimate a suitable dose for subsequent application trials. Furthermore, expected changes in the in 
vivo metabolism may be postulated based on observations from in vitro experiments. is facilitates 
the subsequent analysis, as potentially expected analytes are already foreseen. Additionally, it was 
demonstrated that it is of paramount importance to include male and female volunteers in studies 
evaluating the metabolism of steroids. In both manuscripts it was observed, that detected changes 
in steroid profiles were not completely similar in the male and the female volunteer. As discussed 
previously and reported by literature as well, the steroid profile of females is more challenging to 
interpret and hence needs special aention and in-depth investigations. e knowledge gained 
from these two manuscripts may build a basis to improve interpretation of analytical results in 
future steroid analysis. 
Besides the above-mentioned steroid profiling, additional methods are necessary for the 
identification of synthetic steroids and so called “designer steroids”. Usually screening methods are 
performed, monitoring the presence of drugs themselves and/or known (long-term) metabolites. 
Especially long-term metabolites are of interest for the detection, since substances which are no 
longer administered (e.g. stop of intake before a competition) may hence be detected as well. It is 
furthermore known, that the effect of AAS on the performance is prolonged [80]. A prolonged 
Discussion and Outlook  105 
detection of the substances is hence reasonable and desirable. For the new discovery of long-term 
metabolites, it is of paramount importance to perform metabolic studies. As mentioned earlier in 
this chapter and also in Chapter 2.2 in vitro studies should build the basis for subsequent in vivo 
trials. Results obtained from in vitro experiments can provide valuable information for the planning 
and execution of in vivo studies. Generally, two different approaches for the detection of new 
metabolites are discussed subsequently. First, procedures to detect metabolites of already known 
synthetic steroids are explained. Second, procedures to detect metabolites of unknown and 
potentially novel designer steroids are described. 
In the first case, involving known synthetic steroids, metabolic studies with the compound of 
interest can directly be performed. In vitro experiments can be used to evaluate enzymatic 
contribution and give an idea on which metabolites may be expected in vivo. As the detection of 
metabolites in humans is the ultimate interest, only in vivo application trials or retro perspective 
studies can provide definite information on formed metabolites. For retro perspective studies 
samples which have been detected to contain the substance of interest with already existing 
methods in the past may be re-evaluated. is includes but is not limited to patient samples (for 
approved substances used as pharmaceuticals), samples tested positive for a specific doping 
compound or samples of previous application trials with the same compound but another research 
interest. One problem of retro perspective evaluations is that specific side-conditions possibly 
remain mostly unknown. is may include the time between the intake of the drug and the sample 
collection, the administered amount of drug or endogenous and exogenous factors potentially 
influencing the metabolism. In addition, for samples tested positive for a compound of interest, 
detected metabolites may also derive from another (potentially novel) compound and not from the 
one the sample was tested positive for. Hence, only tentative outcomes can be torn from this kind 
of study. To determine a definite detection window, which is important to know for long-term 
metabolites, a controlled in vivo trial is inevitable. Chapter 2.2.1 describes potential setups and 
some aspects to consider when applying non approved drugs, which is oen the case for doping 
substances. Usually, samples are collected over a sufficiently long time aer the intake of the drug. 
All samples are then analysed, potential new metabolites may be uncovered and their detection 
window determined. 
Once a new long-term metabolite has been identified using in vitro and in vivo methods 
described above, the next challenge is the generation of reference material. Reference compounds 
are of paramount importance in all fields of analytical chemistry. Similarly to other areas, in anti-
doping analysis reference substances are used to unambiguously identify an analytical compound 
and sometimes also quantify the compound of interest. Usually, quantification in anti-doping 
analysis is only required for so called threshold substances which means substances prohibited at 
amounts above a specific predefined concentration in the examined sample, which also includes 
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endogenous steroids. One important aspect for identification of analytes is that the reference 
material had been characterized adequately prior to utilization [60]. 
Manuscript I describes the combined chemical and biochemical synthesis and subsequent 
characterization using high-resolution mass spectrometry (HRMS) of 20OH-NorDHCMT (21), a 
long-term metabolite of the synthetic steroid Oral Turinabol (22). e use of biotechnological 
methods made it possible to relatively easy introduce a hydroxy group to the chemically 
synthesized precursor in a stereoselective way. e work shows that metabolic processes can help 
to simplify organic synthesis of reference compounds especially when stereoselectivity is of 
importance. e substances generated may then be used as reference compounds for the 
unambiguous identification and quantification in routine analysis. 
As mentioned earlier, the second procedure for metabolite detection may be of relevance 
especially for potentially novel and hence unknown designer steroids. As the exact structure of 
these newly designed substances is mostly unknown, neither application trials nor retro 
perspective studies for detection of metabolites are applicable. Metabolic studies may thus help to 
transfer knowledge from related substances and therefor help to predict expected metabolites of 
designer steroids. e investigation on enzymes involved in the metabolite formation of already 
known steroids is therefore of paramount importance. 
Manuscript II comprehensively evaluates structural requirements of CYP21A2 substrates. is 
enzyme had been reported by Parr et al. to play a role in the formation of long-term metabolites in 
a series of 17α-methyl steroids. However not all examined compounds showed the formation of 
17α-methyl-17β-hydroxymethyl metabolites which may serve as potential long-term 
metabolites [33]. Manuscript II lines out strict requirements and accepted structural properties for 
the conversion of 17,17-dimethyl steroids to corresponding 17α-methyl-17β-hydroxymethyl 
metabolites by CYP21A2 using whole cell biotransformations with S.pombe strains recombinantly 
expressing human enzymes (described in detail in Chapter 2.2.2). e presented findings help to 
estimate whether CYP21A2 is of relevance in the metabolite formation of other (unknown 
designer) steroids. To do so, a potential procedure may be the analysis of mass spectra of known 
metabolites for characteristic fragments, as presented in the manuscript. Suspicious samples from 
doping control analysis may then be screened for analytes containing these characteristic 
fragments and potential elemental compositions obtained from HRMS data. is may build the 
basis to detect and postulate a structure for newly discovered designer steroids. Based on these 
structure proposals, promising compounds can be synthesized and compared with the unknown 
analyte for final confirmation. Similar approaches are conceivable in other fields where unknown 
analysis is of interest. 
In conclusion, the results presented in this work contribute to the improvement of methods 
used for the detection of steroids not only in anti-doping analysis. is work shows that this can 
be achieved in different ways. First, by investigating factors which influence the endogenous 
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steroid metabolism and hence lead to altered steroid profiles. Second, by generating reference 
material which helps to unambiguously identify and quantify metabolites. And third, by 
investigating metabolic steps of known compounds and transferring this knowledge to other and 
potentially unknown compounds. Furthermore, the potential of metabolic studies to investigate 
the endocrine disrupting ability of drugs was demonstrated. e impact of this knowledge for 
further risk-assessment and drug development is discussed. 
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6 SUMMARY 
is thesis addresses the steroid metabolism and its role in the detection of steroids. e results 
were achieved by performing metabolic studies in combination with different analytical 
techniques. ree main outcomes were achieved. First, the generation of reference material for a 
long-term metabolite of the synthetic steroid Oral-Turinabol (OT) was presented. e obtained 
results enhance unambiguous detection and quantification of this metabolite and hence help to 
uncover the prohibited OT administration in sports doping. Second, structural requirements and 
tolerated functionalities for substrates of the enzyme Cytochrome P450 subtype 21A2 (CYP21A2) 
were evaluated. ese insights help to extrapolate known metabolic reactions to new and 
potentially unknown compounds. ird, investigations on steroid profile changes caused by the 
intake of non-steroidal anti-inflammatory drugs were described. ese findings provide knowledge 
on substances influencing steroid metabolism, which is of high relevance for accurate steroid 
determination and hence the correct interpretation of analytical results. 
All results were obtained using mainly three models to study steroid metabolism and its 
influenceability. First, incubations with Schizosaccharomyces pombe strains recombinantly 
expressing human CYPs were used to generate reference material in small amounts and to evaluate 
metabolic reactions. Second, incubations with isolated recombinantly expressed human enzymes 
were used to examine metabolic reactions and their influenceability by other drugs. ird, in vivo 
drug administration was used to study steroid metabolism in humans and to investigate whether 
the intake of non-steroidal anti-inflammatory drugs leads to changes in steroid concentrations and 
concentration ratios. To subsequently evaluate the samples generated by the methods described 
above different analytical techniques were utilized. High-resolution mass spectrometry (HRMS) 
was used for quantification and tentative structure identification. Liquid chromatography and gas 
chromatography were both combined with HRMS. Additionally, gas chromatography coupled to 
single or triple quadrupole mass spectrometry was employed to identify and accurately quantify 
compounds where reference material was already available. Finally, fluorometric measurements 
carried out in real time were used to determine kinetic characteristics of enzymatic reactions. 
e results presented in this thesis build a solid base for the refinement of steroid detection. It 
was shown that combinations of in vitro and in vivo metabolic studies and investigations on 
metabolic reactions together with adequate analytical techniques are of high relevance for the 
improvement of steroid detection methods. Furthermore, the results are of relevance to enhance 
methods for generation of reference compounds, to identify potentially new drugs and to re-
evaluate the risk potential of drugs. Further areas that can benefit from the results of this work 
include clinical and toxicological analysis, analysis of environmental and biological samples and 
endocrinology. 
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Finally, the results are of high importance for anti-doping analysis. is field shall be mentioned 
separately as the results presented particularly contribute to tackle challenges relevant in this 
research area.
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ZUSAMMENFASSUNG 
Diese Arbeit befasst sich mit dem Steroidmetabolismus und dessen Rolle in der 
Steroidbestimmung. Die Ergebnisse wurden mit Hilfe von Stoffwechselstudien in Kombination mit 
unterschiedlichen analytischen Techniken erzielt. Drei Hauptergebnisse können formuliert 
werden. Ein erstes Ergebnis ist die Beschreibung der Erzeugung von Referenzmaterial eines 
Langzeitmetaboliten von Oral-Turinabol (OT). Die dabei gewonnenen Erkenntnisse vereinfachen 
den eindeutigen Nachweis und die antifizierung dieses Metaboliten und tragen somit dazu bei, 
die verbotene Einnahme von OT als Doping im Sport zu enthüllen. Weiterhin wurden strukturelle 
Voraussetzungen und tolerierte Funktionalitäten von Substraten des Enzyms Cytochrom P450 
Subtyp 21A2 (CYP21A2) untersucht. Die daraus resultierenden Erkenntnisse ermöglichen die 
Extrapolation bekannter Stoffwechselreaktionen auf neue und möglicherweise unbekannte 
Verbindungen. Als dries Hauptergebnis wurden Untersuchungen beschrieben, die sich mit 
Steroidprofilveränderungen befassen, die durch die Einnahme von Nichtsteroidalen 
Antirheumatika hervorgerufen werden. Dabei wurden Erkenntnisse gewonnen, die einen besseren 
Überblick über Substanzen, welche den Steroidstoffwechsel beeinflussen, ermöglichen. Dieses 
Wissen ist von großer Bedeutung ür den eindeutigen Steroidnachweis und somit die korrekte 
Interpretation von Analysenergebnissen. 
Alle Ergebnisse wurden größtenteils durch die Verwendung von drei Modellen zur 
Untersuchung des Steroidstoffwechsels und seiner Beeinflussbarkeit generiert. Als erstes Modell 
wurden Schizosaccharomyces pombe Stämme genutzt, welche rekombinant humane CYP Enzyme 
exprimieren. Einerseits wurden sie verwendet, um Referenzsubstanzen in kleineren Mengen zu 
erzeugen, andererseits um Stoffwechselreaktionen zu bewerten. Als zweites Modell wurden 
Inkubationen mit isolierten rekombinanten humanen Enzymen durchgeührt, um 
Stoffwechselreaktionen und deren Beeinflussbarkeit durch andere Arzneistoffe zu untersuchen. Als 
dries Modell wurden in vivo Arzneimielanwendungen genutzt, um den Steroidstoffwechsel im 
Menschen zu untersuchen sowie die Auswirkungen der Einnahme von Nichtsteroidalen 
Antirheumatika auf Steroidkonzentrationen und -konzentrationsverhältnisse zu beleuchten. 
Um die durch die oben genannten Methoden erzeugten Proben anschließend zu analysieren, 
wurden verschiedene analytische Techniken verwendet. Hochauflösende Massenspektrometrie 
(HRMS) wurde zur antifizierung und vorläufigen Strukturaulärung genutzt. Dabei wurden 
Flüssigchromatographie und Gaschromatographie gekoppelt mit HRMS angewendet. Zusätzlich 
wurde eine Kombination aus Gaschromatographie gekoppelt mit Single- oder Triple-adrupol 
Massenspektrometrie verwendet um Verbindungen, ür welche Referenzmaterialien bereits 
verügbar waren, nachzuweisen und exakt zu quantifizieren. Abschließend wurden 
fluorometrische Messungen in Echtzeit durchgeührt, um kinetische Kenndaten von 
Enzymreaktionen zu bestimmen. 
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Die im Rahmen dieser Arbeit vorgestellten Erkenntnisse bilden eine zuverlässige Grundlage ür 
die Verbesserung des Steroidnachweises. Es wurde gezeigt, dass eine Kombination aus in vitro und 
in vivo Stoffwechselstudien und Untersuchungen zu Stoffwechselreaktion in Verbindung mit 
geeigneten analytischen Techniken von hohem Stellenwert ür die Verbesserung von 
Steroidnachweismethoden ist. Außerdem sind die Erkenntnisse von Bedeutung, um Methoden zur 
Erzeugung von Referenzmaterialien zu verbessern, potenzielle neue Arzneistoffe zu erkennen und 
das Risikopotenzial von Arzneistoffen neu zu evaluieren. Weitere Gebiete, die von den 
Erkenntnissen dieser Arbeit profitieren können, sind unter Anderem, die klinische und 
toxikologische Analytik, die Umweltanalytik, die Untersuchung von biologischen Proben und die 
Endokrinologie. 
Weiterhin sind die Ergebnisse von hoher Bedeutung ür die Anti-Doping Analytik. Dieses 
Wissenschasfeld soll gesondert genannt werden, da die vorgestellten Ergebnisse dazu beitragen, 
Herausforderungen, die in diesem Gebiet von besonderer Relevanz sind, zu überwinden. 
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